PF-[ADDRESS_626133] OF HIGH -FAT 
MEAL ON THE RELATIVE BIOAVAILABILITY OF P F-07321332 BOOSTED 
WITH RITONAVIR IN HEALTHY ADULT PAR TICIPANTS
Study Intervention Number : PF-
07321332
Study Intervention Name: N/A
USIND Number: [ADDRESS_626134] Number: N/A
ClinicalTrials.gov ID:  N/A
Protocol Number: C4671019
Phase: 1
Brief Title: A Phase [ADDRESS_626135] of High -Fat Meal on the Relative 
Bioavailability  of PF -07321332 Boosted with Ritonavir in Health y Adult Participants
This document and accompanying materials contain confidential information belonging to [COMPANY_007]. Except as 
otherwis e agreed to in writing, by [CONTACT_185586] s, you agree to hold this 
information in confidence and not copy or disclose it to others (except where required by [CONTACT_1289] ) or 
use it for unauthorized purposes. In the event of any act ual or suspected breach of this obligation, [COMPANY_007] 
must be promptly notified.

PF-[ADDRESS_626136] OF TABLES................................................................................................................. ....7
1. PROTOCOL  SUMMARY.....................................................................................................8
1.1. Synopsis .................................................................................................................. ..8
1.2. Schema .................................................................................................................... 11
1.3. Schedule of Activities .............................................................................................12
2. INTRODUCTION ...............................................................................................................1 5
2.1. Study R ationale .......................................................................................................15
2.2. Background .............................................................................................................15
2.2.1. Nonclinical Pharmacology..........................................................................162.2.2. Nonclinical Pharmacokinetics and Metabolism .........................................162.2.3. Nonclinical Safety ......................................................................................162.2.4. Clinical Overview.......................................................................................17
2.3. Benefit/Risk Assessment.........................................................................................20
2.3.1. Risk Assessment .........................................................................................212.3.2. Benefit Assessment.....................................................................................232.3.3. Overall Benefit/Risk Conclusion................................................................23
3. OBJECTIVES AND ENDPOINTS .....................................................................................234. STUDY DESIGN................................................................................................................ .23
4.1. Overall Design.........................................................................................................234.2. Scientific Rationale for Study Design.....................................................................25
4.2.1. Choice of Contraception/Barrier Requirements .........................................25
4.3. Justification for Dose ..............................................................................................25
4.4. End of Study Definition ..........................................................................................26
5. STUDY POPULATION ......................................................................................................26
5.1. Inclusion Criteria.....................................................................................................26
5.2. Exclusion Criteria....................................................................................................275.3. Lifestyle Cons iderations..........................................................................................29
5.3.1. Meals and Dietary Restrictions...................................................................29CCI
CCI
PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 45.3.2. Caffeine, Alcohol, and Tobacco .................................................................30
5.3.3. Activity .......................................................................................................31
5.3.4. Contraception ..............................................................................................31
5.4. Screen Failures ........................................................................................................31
6. STUDY INT
ERVENTION(S) AND CONCOMITANT THERAPY .................................31
6.1. Study  Intervention(s) Administered ........................................................................32
6.1.1. Administration ............................................................................................32
6.2. Preparation, Handling, Storage, and Accountability ...............................................33
6.2.1. Preparation and Dispensing ........................................................................34
6.3. Measures to Minimize Bias: Randomization and Blinding .....................................34
6.3.1. Allocation to Study Intervention ................................................................34
6.4. Study  Intervention Compliance ...............................................................................34
6.5. Dose Modification ...................................................................................................34
6.6. Continued Access to Study  Intervention After the End of the Study ......................34
6.7. Treatment of Overdose
............................................................................................34
6.8. Concomitant Therapy ................................ ................................ .............................. 35
6.8.1. Rescue Medicine .........................................................................................36
7. DI SCONTINUATION O F STUDY INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................36
7.1. D iscontinuation of Study  Intervention ....................................................................36
7.1.1. Potential Cases of Acute Kidney  Injury .....................................................36
7.2. Participant Discontinuation/Withdrawal From the Study .......................................[ADDRESS_626137] to Follow up
....................................................................................................38
8.
STUDY ASSESSMENTS AND PROCEDURES................................ ............................... 38
8.1. Efficacy  Assessments ..............................................................................................39
8.2. Saf ety Assessments .................................................................................................39
8.2.1. Phy sical Examinations ................................................................................40
8.2.2. Vital Signs ..................................................................................................40
[IP_ADDRESS]. Respi[INVESTIGATOR_82218] ........................................................................40
[IP_ADDRESS]. Temperature ..............................................................................41
8.2.3. Electrocardiograms
.....................................................................................41

PF-07321332 
Protocol C4671019Final Protocol, 18 October 2021
PFIZER CONFIDENTIAL
Page 58.2.4. Clinical Safety La boratory Asse ssments ....................................................41
8.2.5. COVID-19 specific assessments.................................................................428.2.6. Pregnancy Testing ......................................................................................42
8.3. Adverse Events, Serious Adverse Events, and Other Safety Reporting .................43
8.3.1. Time Period and Frequency for Collecting AE and SAE Information.......43
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety...............................................[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF...................44
8.3.2. Method of Detecting AEs and SAEs ..........................................................448.3.3. Follow-Up of AEs and SAEs......................................................................448.3.4. Regulatory Reporting Requirements for SAEs...........................................458.3.5. Environmental Exposure, Exposure During Pregnancy or 
Breastfeeding, and Occupational Exposure .....................................................45
[IP_ADDRESS]. Exposure During Pregnancy......................................................[IP_ADDRESS]. Exposure During Breastfeeding ................................................[IP_ADDRESS]. Occupational Exposure .............................................................47
8.3.6. Cardiovascular and Death Events...............................................................478.3.7. Disease-Related Events and/or Disease-Related Outcomes Not 
Qualifying as AEs or SAEs..............................................................................[ADDRESS_626138].............................................................48
[IP_ADDRESS]. Lack of Efficacy........................................................................48
8.3.9. Medical Device Deficiencies......................................................................488.3.10. Medication Errors .....................................................................................48
8.4. Pharmacokinetics ....................................................................................................49
8.4.1. Plasma for Analysis of PF-07321332.........................................................49
8.7. Immunogenicity Assessments .................................................................................51CCI
PF-07321332 
Protocol C4671019Final Protocol, 18 October 2021
PFIZER CONFIDENTIAL
Page 68.8. Health Economics ...................................................................................................51
9. STATISTICAL CONSIDERA TIONS ................................................................................51
9.1. Statistical Hypotheses .............................................................................................519.2. Analysis Sets ...........................................................................................................519.3. Statistical Analyses .................................................................................................52
9.3.1. Primary Endpoint(s)....................................................................................52
[IP_ADDRESS]. Derivation of Pharmacokinetic Parameters...............................[IP_ADDRESS]. Statistical Methods for Pharmacokinetic Data ..........................53
9.3.2. Other Safety Analyses ................................................................................54
9.4. Interim Analyses .....................................................................................................54
9.5. Sample Size Determination.....................................................................................54
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ..........................................................................................................56
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ...............56
10.1.1. Regulatory and Ethical Considerations ....................................................56
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP.........................................................................56
10.1.2. Informed Consent Process ........................................................................5710.1.3. Data Protection .........................................................................................5810.1.4. Committees Structure ...............................................................................58
[IP_ADDRESS]. Data Monitoring Committee ...................................................58
10.1.5. Dissemination of Clinical Study Data ......................................................5810.1.6. Data Qualit y Assurance ............................................................................59
10.1.7. Source Documents....................................................................................6010.1.8. Study and Site Start and Closure ..............................................................6110.1.9. Publication Policy.....................................................................................6210.1.10. Sponsor’s Qualified Medical Personnel .................................................62
10.2. Appendix 2: Clinical Laboratory Tests .................................................................6410.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-Up, and Reporting .....................................................................65
10.3.1. Definition of AE .......................................................................................65
10.3.2. Definition of an SAE ................................................................................66CCI
PF-07321332 
Protocol C4671019Final Protocol, 18 October 2021
PFIZER CONFIDENTIAL
Page 710.3.3. Recording/Reporting and Follow-Up of AEs and/or SAEs During 
the Active Collection Period............................................................................67
10.3.4. Reporting of SAEs....................................................................................71
10.4. Appendix 4: Contraceptive and Barrier Guidance ................................................72
10.4.1. Male Participant Reproductive Inclusion Criteria ....................................7210.4.2. Female Participant Reproductive Inclusion Criteria.................................7210.4.3. Woman of Childbearing Potential ............................................................7310.4.4. Contraception Methods.............................................................................74
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-Up Assessments .......77
10.7. Appendix 7: ECG Findings of Potential Clinical Concern ...................................7910.8. Appendix 8: Abbreviations ...................................................................................[ADDRESS_626139] OF TABLES
Table 1. Treatment Sequences ................................................................................24Table 2. Plasma PF-07321332 PK Parameters Definitions ....................................53Table 3. Protocol-Required Safety Laboratory Assessments .................................64CCI
PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 81.PROTOCOL SUMMARY 
1.1.Synopsis 
Brief Title: A Phase [ADDRESS_626140]. 
Objectives and Endpoints
Objectives Endpoints
Primary: Primary: 
To evaluate the effect of s high-fat meal on the 
exposure sof PF -07321332 boosted with ritonavir
following a single oral dose of PF -07321332 in 
combination with ritonavir using 150mg tablet 
formulation of PF -07321332 .The ratio of AUC last, AUC inf(if data permit) and C maxof 
PF-07321332 .
Secondary: Secondary: 
To characterize the pharmacokinetic parameters of 
PF-07321332 boosted with ritonavir following a 
single oral dose of PF -07321332 in combination with 
ritonavir.
To evaluate the safety and tolerability of 
PF-07321332/ritonavir in healthy participants .Tmax,andt½,CL/F and V z/F(if data permit) .
Assessment of TEAEs, clinical laboratory 
abnormalities, vital signs, and [ADDRESS_626141] of 2 treatments: a single oral dose of 300 mg 
PF-07321332 (2 × 150 mg tablets) under fasted conditions and 3doses of 100 mg ritonavir at 
-12 hour, 0 hour and 12 hour related to PF -07321332 dosing (Treatment A), and a single oral 
dose of 300 mg PF -07321332 (2 × 150 mg tablets) under fed conditions and 3doses of 
100mg ritonavir at -12 hour , 0 hour and 12 hour related to PF -07321332 dosing 
(Treatment B). Approximately  12 healthy  male and/or female participants will be 

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 9randomized into 1 of 2 sequences. Participants who discontinue from the study for non -safet y 
reasons may  be replaced at the sponsor’s discretion in collaboratio n with the Investigator.
Health y participants will be screened to determine eligibility  within [ADDRESS_626142] 12 hours prior to the dosing of 
PF-07321332 on Day  1. On the evening of Day  -1, participants will receive a single oral dose 
of ritonavir 100 mg (
-12 hour relative to PF -07321332 /ritonavir dosing). On the morning of 
Day 1 of each period, participants will receive a single dose of PF-07321332 
300mg/ritonavir 100 mg as per randomization schedule. Study  interventions will be 
administered with approximately  240 mL of ambient temperature water . In fed periods 
(Sequence 2, Period 1 and Sequence 1, Period 2), following an overnight fast of at least 
10hours, participants should begin breakfast approximately  30 minutes prior to 
PF-07321332/ritonavir administration. A high-fat (approximately  50% of total caloric 
content of the meal), high -calorie (approximately  800 to 1000 calories) breakfast will be 
consumed over approximately  a 20 -minute interval with PF -07321332/ritonavir administered 
within approximately  [ADDRESS_626143] dose. Period 2 will begin on Study  Day  4 (referred to as Period 2, Day -1). 
Participants will be discharged from the CRU on Period 2, Day 3 following completion of all 
assessments.
If a participant has an y clinically  significant, stud y related abnormalities at the conclusion of 
a scheduled inpatient portion of the study , the [COMPANY_007] medical monitor (or designated 
representative) should be notified and the participant may  be asked to remain in the CRU 
until such abnormali
ties are deemed not clinicall y significant, or it is safe for outpatient 
follow -up.
A safet y follow- up call will be made to participants approximately  28 to 35 day s from 
administration of the final dose of study  intervention.
Number of Participants
Approxi mately  12participants will be randomly  assigned to study  intervention .
Note: 
“Enrolled ”means a participant ’s, or his or her legall y authorized representative’s, 
agreement to participate in a clinical study following completion of the informed consent 
process and screening . A participant will be considered enrolled if the informed consent is 
not withdrawn prior to participating in an y stud y activ ity after screening .Potential 
participants who are screened for the purpose of determining eligibility  for the study , but do 
not participate in the study, are not considered enrolled, unless otherwise specified b y the 
protocol.

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 10Intervention Groups and Dur ation
Each participant will be screened to determine eligibility  within 28 days prior to study  
treatment. Eligible participants will report to the CRU on Day  -1, Period 1 and will be 
required to stay  in the CRU for 
8 day s and 7 nights. A safet y follow- up call will be made to 
participants approximately 28 to 35 day s from administration of the final dose of study  
intervention. 
Each enrolled participant will participate in 2 study periods to receive 2 different treatments 
according to the sequence determined b y randomization: 
Treatment A:  Single oral dose of 300 mg PF -07321332 (2 × 150 mg tablets) under fasted 
conditions and 3 doses of 100 mg ritonavir at -12 hour, 0 hour and 12 hour related to 
PF-07321332 dosing . (Reference)
Treatment B: Single oral dose of 300 mg PF -07321332 (2 × 150 mg tablets) under fed 
conditions and 3 doses of 100 mg ritonavir at -12 hour, 0 hour and 12 hour related to 
PF-
07321332 dosing. (Test)
Participants will be randomly  assigned to 1 of 2 sequences as follows: 
Period 1 Washout
(4days between 
PF-07321332 dosing)Period 2
Sequence 1 (n=6) Treatment A Treatment B
Sequence 2 (n=6) Treatment B Treatment A
Data Monitoring Committee or Other Independent Oversight Committee : None
Statistical Methods
Pharmacokinetics Analysis
The PK concentration population is defined as all participants randoml y assigned to stud y 
intervention and who take at least [ADDRESS_626144] noncompartmental method 
of anal ysis. Actual PK sampling times will be used in the derivation of PF -07321332 PK 
parameters when ava ilable, otherwise nominal times will be used. The PF- 07321332 plasma 
PK parameters will be summarized descriptively  by [CONTACT_3148]. Plasma concentrations will be 
listed and summarized descriptively  by [CONTACT_3148], and nominal PK sampling time. Individual 
participant and summary  profiles (mean and median plots) of the plasma concentration time 
data will be plotted by [CONTACT_486832], respectively . 

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 11Natural log transformed AUC inf(if data permit), AUC lastand C maxwill be anal yzed using a
mixed effect model with sequence, period and treatment as fixed effects and participant 
within sequence as a random effect. Estimates of the adjusted mean differences (Test -
Reference) and corresponding 90% CIs will be obtained from the model. The adjusted mean 
differences and 90% CIs for the differences will be exponentiated to provide estimates of the 
ratio of adjusted geometric means (Test/Reference) and 90% CI for the ratios. Treatment A 
(PF-07321332/ritonavir administered under fasted condition) is the Reference treatment and 
Treatment B (PF -07321332/ritonavir administered under fedcondition) is the Test treatment. 
Safety Analysis
All safet y anal yses will be performed on the safet y anal ysis set, which is defined as all
participants randoml y assigned t o study  intervention and who take at least 1 dose of study  
intervention. Safet y data will be presented in tabular and/or graphical format and summarized 
descriptivel y, where appropriate.
1.2.Schema
Not a pplicable .

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 121.3. S chedule of Activ ities
The SoA table provides an overview of the protocol visits and procedures. Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with th e 
protocol. 
The investigator may  sche dule visits (unplanned visits) in addition to those listed i n the SoA table , in order to conduct evaluations or 
assessments required to protect the well -being of the participant .
Visit Identifier
Abbreviations used in this 
table may be found in 
Appendix 8ScreeningaPeriods 1 -2b 28-35 days
(Follow -Up)Early 
Termination/
Discontinuation
Days Relative to Day 1 Days
-28 to -2Day -1 Day 1 Day 2 Day 3 Day 
28-35w
Hours After Dose 00.5 11.5 22.5 3 4 6 812 16 24 48
Informed consent X
CRU ConfinementcX              X
Inclusion/exclusion criteria X Xu
Medical/medication history 
(update)dX Xu
DemographyeX
Physical examfX Xu
Safety laboratory (including 
aPTT, PT -INR, Fibrinogen , 
and eGFR )gX XuX X
FSHhX
Urine drug testingiX Xu
Serology: HBsAg, HBsAb, 
HBcAb, HCVAb, and HIVjX
Pregnancy test (WOCBP 
only)X XuX X
Contraception checkkX XuX
Single supi[INVESTIGATOR_050] 12 -lead ECGlX XvX X
Vital signs 
(BP/PR/RR /temperature )mX XvX X
COVID -19 questionnairenX Xu

PF-07321332 
Protocol C4671019Final Protocol, 18 October 2021
PFIZER CONFIDENTIAL
Page 13Visit Identifier
Abbreviations used in this 
table may be found in 
Appendix 8ScreeningaPeriods 1-2b 28-35 days
(Follow-Up)Early 
Termination/
Discontinuation
Days Relative to Day 1 Days
-28 to -2Day -1 Day 1 Day 2 Day 3 Day 
28-35w
Hours After Dose 00.5 11.5 22.5 3 4 6 812 16 24 48
COVID-19 testingoXXu  
Ritonavir administrationpX X
PF-07321332/ritonavir 
administrationqX
PK Blood Sampling for 
PF-07321332rXXXXXXXXXXX X X X X
 
 
Serious and nonserious AE 
monitoringX → →→→→→→→→→→→ → → → XX
Concomitant treatments  X → → → → → → → → → → → → X X
CRU dischargetX
a. Screening will be performed within [ADDRESS_626145] dose of PF-07321332/ritonavir. 
b. Period 2 will begin on Study Period1, Day 4 (referred to as Period 2, Day -1).
c. Participants will be admitted to the CRU at least -12 hours prior to PF-07321332 dose on Day 1. Participants will be discharged  on Day 3 of Period 2 following the final 
assessments. 
d. Medical history will include a history of prior illegal drug, alcohol, and tobacco use, as well as blood donation within prio r 60 days. Medical history will be recorded at 
screening and updated on Day -1 of Period 1. 
e. Demographics will include participant race, ethnicity, age, and gender during the screening visit. 
f. Physical exam will be performed by [CONTACT_487227] -1 of Period 1 only (height and weight must be obtained at screening 
to obtain BMI for eligibility criteria). A targeted PE may be performed at other designated time points at the discretion of the  investigator. 
g. Safety laboratory assessments including urinalysis, hematology, chemistry and coagulation will be performed at the indicated time-points. All the safety laboratory samples 
must be collected following at least a 4-hour fast. Additional safety laboratory assessments may be performed at any time at th e discretion of the investigator. 
h. For postmenopausal (amenorrheic for at least 12 consecutive months) female participants only.i. Urine drug (mandatory) and alcohol breath test (at discretion of investigator) will be performed at screening and on Day -1. These tests may be performed at any other time at 
the discretion of the investigator.
j. HBsAb will be tested if HBsAg and/or HBcAb are positive.
k. The investigator or his/her designee will discuss with the participant the need to use highly effective contraception consist ently and correctly according to contraception 
guidelines.
l. All ECG assessments will be made after at least a [ADDRESS_626146] practice.CCI
PF-07321332 
Protocol C4671019Final Protocol, 18 October 2021
PFIZER CONFIDENTIAL
Page 14Visit Identifier
Abbreviations used in this 
table may be found in 
Appendix 8ScreeningaPeriods 1-2b 28-35 days
(Follow-Up)Early 
Termination/
Discontinuation
Days Relative to Day [ADDRESS_626147] will be performed after 
4 days (ie, upon completion of 4 × 24 hours in house), or if they develop COVID-19 like symptoms.
p. Ritonavir will be administered orally -12 hours and 12 hours relative to PF-07321332/ritonavir dosing on Day 1. 
q. PF-07321332/ritonavir will be administered orally after overnight fasting on Day 1 of each treatment period.r. One (approximately 4 mL) blood sample for PK analysis of PF-[ADDRESS_626148] 
SARS-CoV-2 3CLpro(Ki = 0.[ZIP_CODE] μM) in a biochemical enzymatic assay. Since the 
3CLprofrom human coronaviruses are structurally similar and share a high degree of 
conservation at the active site of the enzyme, the ability of PF-07321332 to inhibit the 3CLpro
of other coronaviruses (SARS-CoV-1 and HCoV-229E, MERS, HCoV-OC43, HCoV-HKU1, and HCoV-NL63) was also confirmed, indicating a potential for broad spectrum anti-coronavirus activity. The coronavirus 3CL protease is a virally encoded enzyme that is critical to the SARS-CoV-2 replication cycle, analogous to other obligatory virally encoded proteases (eg, HIV Protease, HCV Protease).
2PF-[ADDRESS_626149] for clearance of 
PF-07321332 in vitro in liver microsomes (mouse, rat, hamster, rabbit, monkey, and human), hepatocytes (rat, monkey, and human), and in vivo in rat and monkey after repeat oral dosing. In a reaction phenotypi[INVESTIGATOR_487219], CYP3A4 was predicted to be the major contributor (f
m= 0.99) to 
the in vitro oxidative metabolism of PF-07321332. No significant CYP3A5 contribution is expected to the metabolism of PF-07321332. 
Additional information of the nonclinical PK and metabolism of PF-[ADDRESS_626150] dose administered (1000 mg/kg 
and 600 mg/kg in the rat and monkey studies, respectivel y). PF- 07321332-related 
 non-adverse, test article-related clinical findings included sporadic occurrence of emesis 
with slight body weight decreases in monkeys. Monitorable and reversible clinical pathology findings included those possibly suggestive of low-grade inflammation (in rats and monkeys) or alterations in the coagulation pathways (in rats only) without clinical or microscopic correlates. Other  non-adverse  clinical pathology findings were likely due to the emesis and 
subsequent dehydration in monkeys. In rats administered 1000 mg/kg/day, lower mean absolute and relative heart weights (females) and higher absolute and relative liver weights (both sexes) were observed relative to controls. The lower heart weights had no microscopic correlates and were fully reversed at the end of the 2-week recovery period. Higher liver weights correlated with reversible,  non-adverse  microscopic findings of minimal to mild 
severity in the liver and thyroid gland consistent with adaptive changes related to microsomal enzyme induction.
PF-07321332 was not  mutagenic  or clastogenic in in vitro genetic toxicity studies and was 
negative in the in vivo rat micronucleus assay incorporated into the GLP repeat-dose rat toxicity study. 
The nonclinical studies performed  adequately  support the oral administration of 
PF-07321332 in the clinic for up to 14 days.  
Further details of the nonclinical safety program are provided in the current IB.CCI
PF-07321332 
Protocol C4671019Final Protocol, 18 October 2021
PFIZER CONFIDENTIAL
Page 172.2.4. Clinical Overview
Safety, tolerability and PK of PF-07321332 in healthy adult participants was explored in 
Phase 1 FIH Study (C4671001). Study C4671001 was a five-part study consisting of SAD (PART-1), MAD (PART-2), relative bioavailability/food effect (PART-3), metabolism and excretion study (PART-4) and supratherapeutic exposure cohort (PART-5). PART-[ADDRESS_626151] of an oral tablet formulation. PART-4 is an open-label, non-randomized, single-period to evaluate the metabolism and excretion of PF-07321332. PART-5 was a double-blind, sponsor-open, randomized, cross-over study to evaluate safety and tolerability at supratherapeutic exposures.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
PF-07321332 
Protocol C4671019Final Protocol, 18 October 2021
PFIZER CONFIDENTIAL
Page 18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
PF-07321332 
Protocol C4671019Final Protocol, 18 October 2021
PFIZER CONFIDENTIAL
Page 19 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
PF-07321332 
Protocol C4671019Final Protocol, 18 October 2021
PFIZER CONFIDENTIAL
Page 20 
 
 
 
 
 
 
 
2.3. Benefit/Risk Assessment
PF-07321332/ritonavir are not expected to provide any clinical benefit to healthy participants 
in this study. This study is designed primarily to estimate relative bioavailability ofPF-07321332 150 mg tablet compared to PF-07321332 100 mg tablet formulation in healthy adult participants and bridge PK between these 2 formulations. 
 
 
 
 
 
 
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events of PF-07321332 may be found in the IB, which is the SRSD for PF-07321332. The SRSD for ritonavir
4is USPI.CCI
CCI
PF-07321332 
Protocol C4671019Final Protocol, 18 October 2021
PFIZER CONFIDENTIAL
Page 212.3.1. Risk Assessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Study Intervention(s) PF-07321332
Emesis Sporadic emesis was observed at ≥100 mg/kg/day 
of PF-07321332 in the 15-day NHP toxicology study (See IB).  
 
 
 As this is an investigational agent, there is some 
risk that is mitigated by [CONTACT_486823], etc. If needed, palliative care or antiemetics may be provided.
Neuronal and pulmonary effects Transient effect in rat neuronal and pulmonary 
endpoints were observed in rat toxicology study at the high dose level (1000 mg/kg as single dose; See IB).  
 
 
 
 Vital signs, including respi[INVESTIGATOR_697], will be 
monitored for pulmonary effect. There will be close observation of AEs for any signs of neuronal effect. 
Hemodynamic effects Low level inflammation (increase in fibrinogen) in 
15-day NHP toxicology study and changes in 
platelets, globulin and albumin/globulin ratio and coagulation system (increase in PT and aPTT) in 14-day rat toxicology study (See IB).  
 
 
 
 
 Fibrinogen, platelets, PT-INR and aPTT, albumin 
and total proteins will be monitored. CCI
CCI
CCI
PF-07321332 
Protocol C4671019Final Protocol, 18 October 2021
PFIZER CONFIDENTIAL
Page 22Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
 
Study Intervention(s) Ritonavir
Gastrointestinal disturbances (including diarrhea, 
nausea, vomiting and abdominal pain).Frequently reported adverse reaction in HIV 
patients at 600 mg BID.Lower dose of 100 mg twice daily is used in this 
study. There will be close observation of AEs. If 
needed, anti-emetics may be provided. 
Neurological disturbances (eg, paresthesia, including oral paresthesia, dysgeusia and dizziness).Frequently reported adverse reaction in HIV 
patients at 600 mg BID.Lower dose used in this study. There will be 
close observation of AEs. 
Rash (most commonly reported as erythematous and maculopapular, followed by [CONTACT_108135]).Frequently reported adverse reaction in HIV 
patients at 600 mg BID.Lower dose used in this study. There will be 
close observation of AEs and monitoring through targeted physical exams. If needed, palliative care may be provided. 
Fatigue/Asthenia Frequently reported adverse reaction in HIV 
patients at [ADDRESS_626152]-marketing in HIV patients.Lower dose used in this study. There will be 
close observation of AEs and renal function.CCI
PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 232.3.2. Benefit Assessment
PF-07321332/ritonavir will not provide any  clinical benefit to healthy  participants in this 
study . Any anticipated benefit to participants would be in terms of contribution to the process
of developi[INVESTIGATOR_007] a new therapy  in an area of unmet medical need.
2.3.3. Overall Benefit /Risk Conclusion
PF-07321332/ritonavir is not expected to provide any  clinical benefit to healthy  participants 
in this study . Taking into account the measures taken to minimize r isk to participants of this 
study , the potential risks identified in association with PF-
07321332/ritonavir are justified b y 
the anticipated benefits , in terms of contribution to the process of developi[INVESTIGATOR_007] a new therap y 
in an area of unmet medical need.
3.OBJECTIVES AND ENDPO INTS
Objectives Endpoints
Primary : Primary : 
To evaluate the effect of a high-fat meal on the 
exposure of PF-07321332 boosted with ritonavir 
following a single oral dose of PF -07321332 in 
combination with ritonavir using 150 mg tablet 
formulation of PF-07321332 .The ratio of AUC last, AUC inf(if data permit) and C maxof 
PF-07321332 .
Secondary: Secondary : 
To characterize the pharmacokinetic parameters of 
PF-07321332 boosted with ritonavir following a 
single oral dose of PF -07321332 in combination with 
ritonavir.
To evaluate the safety and tolerability of 
PF-07321332/ritonavir in healthy participants .Tmax, and t ½, CL/F and V z/F(if data permit) .
Assessment of TEAEs, clinical laboratory 
abnormalities, vital signs, and [ADDRESS_626153] of 2 treatments: a single oral dose of 
300mg PF -07321332 (2 × 150 mg tablets) under fasted conditions and 3 doses of 100 mg 
ritonavir at -12 hour, 0 hour and 12 hour related to PF -07321332 dosing (Treatment A), and a 
single oral dose of 300 mg PF-07321332 (2 × 150 mg tablet s)under fed conditions and 
3doses of 100 mg ritonavir at -12 hour, 0 hour and 12 hour related to PF -07321332 dosing 
(Treatment B).There will be a total of 2 treatment sequences shown in Table 1with the 
assigned Treatments A or B in each treatment period.
A total of approximately  12 healthy  male and/or female participants will be randomly  
assigned to investigational product such that approximately  6 participants wil lbe enrolled to 

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 24each sequence. Participants who withdraw from the study  may  be replaced at the sponsor’s 
discretion in collaboration with the I nvestigator .
Each enrolled participant will participate in 2 study periods to receive 2 different treatments
according to the sequence determined b y randomization : 
Treatment A: Single oral dose of 300 mg PF -07321332 (2 × 150 mg tablets) under fasted 
conditions and 3 doses of 100 mg ritonavir at -12 hour, 0 hour and 12 hour related to 
PF-07321332 dosing . (Reference)
Treatment B: Single oral dose of 300mg PF -07321332 (2 × 150 mg tablets) under fed 
conditions and 3 doses of 
100mg ritonavir at -12 hour, 0 hour and 12 hour related to 
PF-07321332 dosing . (Test)
Participants will be randomly  assigned to 1 of 2 sequences as in Table 1. Serial PK samples 
will be collected at timepoints shown in SoA.
Participants will be discharged on Period 2, following completion of all assessments.
Table 1. Treatment Sequences
Period 1 Washout
(
4days between 
PF-07321332 dosing)Period 2
Sequence 1 (n=6) Treatment A Treatment B
Sequence 2 (n=6) Treatment B Treatment A
The total planned duration of participation, from the s creening visit to the last Follow -up 
phone call, is approximately  [ADDRESS_626154] 12 hours prior to the dosing of 
PF-07321332 on Day  1. On the evening of Day  -1, participants will receive a single oral dose 
of ritonavir 100 mg (
-12 hour relative to PF -07321332 /ritonavir dosing). On the morning of 
Day 1 of each period, participa nts will receive a single dose of PF -07321332 
300mg/ritonavir 100 mg as per randomization schedule. Study  interventions will be 
administered with approximately  240 mL of ambient temperature water.  In fed periods 
(Sequence 2, Period 1 and Sequence 1, Peri od 2), following an overnight fast of at least 
10hours, participants should begin breakfast approximately  30 minutes prior to 
PF-07321332/ritonavir administration. A high-fat (approximately  50% of total caloric 
content of the meal), high -calorie (approxim ately  800 to 1000 calories) breakfast will be 
consumed over approximately  a 20 -minute interval with PF -07321332/ritonavir administered 
within approximately  [ADDRESS_626155] dose. Period 2 will begin on Study  Day  4 (referred to as Period 2, Day  -1). 

PF-[ADDRESS_626156] 8 days and 7 nights and 
discharged at the discretion of the investigator. If a participant has any clinically significant, study related abnormalities at the conclusion of a scheduled inpatient portion of the study, the [COMPANY_007] medical monitor (or designated representative) should be notified and the participant may be asked to remain in the CRU until such abnormalities are deemed not clinically significant, or it is safe for outpatient follow-up.  A safety follow-up call will be made to participants approximately [ADDRESS_626157]. Between 
each treatment period, a minimum of 4-day washout is proposed to minimize any residual PF-07321332 concentrations prior to start of the next period, as PF-07321332 has a half-life of approximately 6 to13 hours when co-administered with ritonavir.
4.2.1. Choice of Contraception/Barrier Requirements
Human reproductive safety data are limited for PF-07321332, but there is no suspi[INVESTIGATOR_22742]. Therefore, the use of a highly effective method of contraception is required (see Appendix 4 ).
 
4.3. Justification for Dose
The dose of 300 mg PF-07321332/100 mg ritonavir for 5 days is the intended therapeutic 
dose and duration to be evaluated in Phase 2/[ADDRESS_626158] dose evaluated in the Phase 1 study (C4671001) and is expected to be safe and well tolerated.
This study is designed to evaluate the effect of a high-fat meal on the relative bioavailability 
of PF-07321332 150 mg tablet in healthy adult participants at intended therapeutic dose. Therefore, a single oral dose 300 mg PF-07321332/[ADDRESS_626159] of ritonavir as CYP3A4 inhibitor, 100 mg ritonavir will be dosed prior to PF-07321332/ritonavir administration.CCI
PF-[ADDRESS_626160] completed the study  if he/she has completed all periods of 
the study , including the last scheduled procedure shown in the SoA.
5.STUDY POPULATION
This study  can fulfill its objectives only  if appropriate participant s are enrolled. The 
following eligibility  criteria are designed to select participant s for whom participa tion in the 
study  is considered appropriate. All relevant medical and nonmedical conditions should be 
taken into consideration when deciding whether a particular participant is suitable for this 
protocol .
Prospective approval of protocol deviations to recruitment and enrollment criteria ,also 
known as protocol waivers or exemptions, is not permitted .
5.1.
Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Age and Sex :
1. P articipants ≥18 years o f age, inclusive, at the time of signing the ICD.
Refer to Appendix 4 for reproductive criteria for male ( Section 10.4.1) and female 
(Section 10.4.2) participants.
Type of Participant and Disease Characteristics:
2.Male and female participants who are overtl y healthy as determined b y medical 
evaluation including medical history , phy sical exa mination, laboratory  tests, 
vital 
signsand 12-lead ECG s .
3.Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests, lifesty le considerations, and other study  procedures.
4.Female participants of childbearing potential must have a negative pregnancy  test.
Weight:
5.BMI of 17.5 to 30.5 kg/m2; and a total body  weight >50 kg (110 lb).

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 27Informed Consent:
6.Capable of giving signed informed consent as described in Appendix 1,which 
includes compliance with the requirements and restrictions listed in the I C
Dand in 
this protocol.
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Positive test result (RT- PCR ) for SARS -CoV -2 infection at the time of screening or 
Day -1.
2.Evidence or history  of clinically  significant hematological, renal, endocrine, 
pulmonary , gastrointestinal, cardiovascular, hepatic, psy
chiatric, neurologic al, or 
allergic disease (including dr ug allergies, but excluding untreated, as ymptomatic, 
seasonal allergies at the time of dosing) .
3.Clinically  relevant abnormalities requiring treatment (eg, acute m yocardial infarction, 
unstable ischemic conditions, evidence of ventricular dysfunction, serio us tachy -or 
brady-arrhy thmias) or indicating serious underl ying heart disease (eg, prolonged PR 
interval, cardiomyopathy, heart failure, underly ing structural heart disease, Wolff 
Parkinson- White sy ndrome). 
4.Any condition possibly  affecting drug absorptio n (eg, gastrectomy , cholecy stectom y
).
5.History  of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, HBsAg, 
or HCVAb. Hepatitis B vaccination is allowed.
6.Other medical or psy chiatric condition including recent (within the past year) or 
active suicidal ideation /behavior or laboratory  abnormality  or other conditions or 
situations related to COVID -19 pandemic (eg ,
contact [CONTACT_216478], residence, 
or travel to an area with high incidence) that may  increase the risk of study 
participati on or, in the investigator’s judgment, make the participant inappropriate for 
thestudy .
Prior/Concomitant Therapy:
7.Use of prescription or nonprescription drugs and dietary  and herbal supplements 
within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention . Refer to 
Section 6.8Concomitant Therap yfor additional details.
Concomitant use of an y medications or substances that are strong inducer s of
CYP3A4 are prohibited within [ADDRESS_626161] dose of 
PF-07321332/ritonavir and during stud y treatment.

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 288.Current use of any prohibited concomitant medication(s) or those unwilling/unable to 
use a permitted concomitant medication(s). Refer to Section 6.[ADDRESS_626162] received a COVID -19 vaccine within 7 day s before screening or 
admission, or who are to be vaccinated with a COVID -19 vaccine at any time during 
the study  confinement period.
Prior/Concurrent Clinical Study Experience:
10.Previous administration with an investigational drug within 30 days (or as determined 
by [CONTACT_19970]) or [ADDRESS_626163] dose of study  intervention
used in this study  (whichever is longer). Participants who have participated in 
previous clinical trials with PF -07321332 may  be eligible to participate in this study  
as long as they  meet all other criteria. 
Diagnostic Assessments:
11.A positive urine drug 
test.
12.Screening supi[INVESTIGATOR_30991] ≥140 mmHg (s ystolic) or ≥90mmHg (diastolic), following at 
least [ADDRESS_626164]. If BP is ≥140 mmHg (s ystolic) or ≥90mmHg 
(diastolic), the BP should be repeated 2 more times and the average of the 3 BP 
values should be used to determine the participant’s eligibility .
13.Baseline standard 
12-lead ECG that demonstrates clinically  relevant abnormalities 
that may  affect participant safet y or interpretation of study results (eg, baseline QTc F
interval >[ADDRESS_626165] -degree AV block, or serious brady arrhy thmias or tachy arrhy thmias). 
If the baseline uncorrected QT interva l is >450 msec, this interval should be 
rate-corrected using the Fridericia method and the resulting QTcF should be used for 
decision making and reporting. If QTc Fexceeds 450 msec, or QRS exceeds 
120msec, the ECG should be repeated 2 more times and the a verage of the 3 QTcFor 
QRS values should be used to determine the participant’s eligibility . 
Computer -interpreted ECGs should be overread b y a physician experienced in 
reading ECGs before excluding a participant.   
14. Participants with ANY of the following a bnormalities in clinical laboratory  tests at 
screening, as assessed b y the study -specific laboratory  and confirmed b y a single 
repeat test, if deemed necessary : 
AST or ALT level ≥1.25 ×ULN;
Total bilirubin level ≥1.5 × ULN; participants with a history  ofGilbert ’s 
syndrome may  have direct bilirubin measured and would be eligible for this study  
provided the direct bilirubin level is ≤ ULN.

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 29eGFR <90 mL/min/1.73 m2with 10% variation based on the CKD -EPI [INVESTIGATOR_10908].
Other Exclusions:
15.History  of alcohol abuse or binge drinking and/or any  other illicit drug use or 
dependence within 6 months of s creening. Binge drinking is defined as a pattern of 
5(male) and 4 (female) or more alcoholic drinks in about 2 hours . As a general rule, 
alcohol intake should not exceed 14 units per week (1 unit=
8ounces [240 mL] beer, 
1ounce [30mL] of 40% spi[INVESTIGATOR_107060] 3 ounces [90mL] of wine).
16. Use of tobacco or nicotine containing products in excess of the equivalents of 5 
cigarettes per day  or 2 chews of toba cco per day .
17.Blood donation (excluding plasma donations) of approximately  1pi[INVESTIGATOR_11731] (500 mL) or 
more within [ADDRESS_626166] of the 
study , site staff otherwise supervised by  [CONTACT_093], and their respective family  
members .
21.History  of sensitivity  reactions to ritonavir, or any of the formulation components of 
PF-07321332 or ritonavir.
22.Pregnant or breastfeeding women.
5.3.Lifestyle Considerations
The following guidelines are provided:
5.3.1. Meals and Dietary Restrictions
Participant s must abstain from all food and drink (except water) at least 4 hours prior 
to any  safety laboratory  evaluations and 10 hours prior to the collection of the predose 
PK sample on Day  1 of each Period.
For the fed period s(Sequence 2, Period 1 and Sequence 1, Period 2 ) only , the FDA 
guidance for evaluation of a food effect on bioavailability  recommends using meal 
conditions that are expected to provide the greatest effects on gastrointestinal 
physiology  so that systemic dru g availability  is maximally  affected. Therefore, a 
high-fat(approximately  50% of total caloric content of the meal), high-calorie 
(approximately 800 to 1000 calories) meal will be used for the evaluation of a food 
effect in this study . The provided meal w ill be similar in composition to the meal 
referenced in the FDA guidance on food -effect bioavailability  and fed bioequivalence 

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 30studies .5OnDay 1 of the fed period s (Sequence 2, Period 1 and Sequence 1, Period 
2), following an overnight fast of at least [ADDRESS_626167] approximately  30 minutes prior to PF-
07321332/ritonavir administration. 
The breakfast will be consumed over approximately a 20 -minute interval with 
PF-07321332/ritonavir administered within approximately  [ADDRESS_626168]. There 
are no water restrictions prior to and after dosing.
For the fasted periods (Sequence 1, Period 1 and Sequence 2, Period 2), w ater is 
permitted until 1 hour prior to study  intervention administration.  Water may be 
consumed without restriction beginning 1 hour after dosing. Noncaffeinated drinks 
(except grapefruit or grapefruit
-related citrus fruit juices—see below) may  be 
consumed with meals and the evenin g snack .
Lunch will be provided approximately  4hours after PF -07321332/ritonavir dosing.
Dinner will be provided approximately  30 mi nutes prior to ritonavir administration at 
-12 hours and 12 hours. The dinner will be consumed over approximately  a 20-minute 
interval with ritonavir administered within approximately  10minutes of completion 
of the meal.
An evening snack may  be permitted.
Participants will refrain from consuming red wine, grapefruit, or grapefruit -related 
citrus fruits (eg, Seville ora nges, pomelos, fruit juices) from [ADDRESS_626169] 
dose of study  intervention until collection of the final PK blood sample.  
While participants are confined, the irtotal daily  nutritional composition should be 
approximately  55% carbohy drate, 30% fat, and 15% protein. The dail y caloric intake 
per participant should not exceed approximately  3200 kcal during the fasting periods 
of the study .
5.3.2. Caffeine, Alcohol, and Tobacco
Participant s will abstain from caffeine -
containing products for 24 hours prior to the 
start of dosing until collection of the final PK sample of each study  period.  
Participant s will abstain from alcohol for 24 hours prior ( except as stated above for 
red wine) to admission to the CRU and continue abstaining from alcohol until 
collection of the final PK sample of each study  period. Participant s may  undergo an 
alcohol breath test or blood alcohol test at the discretion of the investigator.
Participant s will abstai n from the use of tobacco -or nicotine -containing products for 
24 hours prior to dosing and during confinement in the CRU. 

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 315.3.3. Activity
Participants will abstain from strenuous exercise (eg, heav y lifting, weight training, 
calisthenics, aerobics) for at least 48hours prior to each blood collection for clinical 
laboratory  tests. Walking at a normal pace will be permitted;
In order to standardize the conditions on PK sampling day s, participant s will be 
required to refrain from ly ing down (except when required f or BP, respi[INVESTIGATOR_2842], 
pulse rate , and ECG measurements), eating, and drinking beverages other than water 
during the first 4 hours after PF -07321332/ ritonavir dosing;
Participant s will be confined to the procedure room for the first 4 hours after dosing 
on Day 1, except to use the bathroom. After this, participant s may  be ambulatory  but 
should not engage in strenuous activities.
5.3.4. Contraception
The investigator or his or her designee, in consultation with the participant , will confirm that 
the participant has selected an appropriate method of contraception for the individual 
participant and his or her partner(s) from the permitted list of contraception methods (see 
Appendix 4 Section 10.4.4 )and will confirm that the participant has been instructed in its 
consistent and correct use. At time points indicated in the schedule of activities ( SoA), the 
investigator or designee will inform the participant of the need to use highly  effective 
contraception consistently and correctl y and document the conversation and the participant ’s 
affirmation in the participant ’s chart ( participant s need to affirm their consistent and correct 
use of at least 1 of the selected methods of contraception) considering that their risk for 
pregnancy  may  have changed since the last visit . In addition, the investigator or designee will 
instruct the participant to call immediately  if the selected contraception method is 
discontinued or if pregnancy
 is known or suspected in the participant or partner.
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinica l study  but 
are not subsequently  enrolled in the study . Screen failure data are collected and remain as 
source and are not reported on the CRF .
Individuals who do not meet the criteria for participation in this study  (screen failure) may  be 
rescreened. 
6.STUDY INTERVENTION(S ) AND CONCOMITANT TH ERAPY
Study  intervention is defined as any  investigational intervention(s), marketed product(s), 
placebo, medical device(s) , or study  procedure(s) intended to be administered to a study  
participant according to the study  protocol.
For the purposes of this protocol, study  intervention refers to PF-07321332 and ritonavir .

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 326.1.Study Intervention(s) Administered
150 mg PF -07321332 t ablets will be supplied b y the sponsor to the CRU in bulk along with 
individual dosing containers for unit dosing.
Commer cially available 100 mg ritonavir tablets will be supplied by  [CONTACT_47365] .
6.1.1. Administration
Investigational products will be administered orally  and according to the conditions 
described in the SoA section and Protocol Section 5.3.1 Meals and Dietary  Restrictions .
For fasted period (Sequence 1, Period 1 and Sequence 2, Period 2) :
On Day -1, 12 hours prior to dosing of PF- 07321332, participants will receive a 100 mg
ritonavir tablet (as 1 × 100 mg) with approximately  [ADDRESS_626170] 10 hours, the participants will receive
300 mg PF -07321332 (as 2 × 150 mg tablets) with 100 mg ritonavir (as 1 × 100 mg 
tablet) administered orally at approximately  08:00 hours (plus or minus 2 hours) without 
breakfast/standard meal on Day  1. 12 hours after dosing of PF- 07321332, participants 
will receive a 100 mg ritonavir tablet (as 1 × 100 mg) with approximately  240 mL  
ambient temperature water.
For fed periods (Sequence 2, Period 1 and Sequence 1, Period 2 ): 
On Day  -1, 12 hours prior to dosing of PF-07321332, participants will receive a 100 mg
ritonavir tablet (as 1 × 100 mg) with approximately  [ADDRESS_626171] approximately  30 minutes prior to dosing which is to be completed with in
approximately  20minutes as outlined in Section 5.3.1 (Meals and Dietary  Restrictions ). 
The participants will then receive 300 mg PF -07321332 (as 2 × 150 mg tablets) with 
100
mg ritonavir (as 1 × 100 mg tablet) administered orall y at approximately 08:00 hours 
(plus or minus 2 hours). 12 hours after dosing of PF-07321332, participants will receive a 
100 mg ritonavir tablet (as 1 × 100 mg) with approximately  240 mL ambient temperature 
water.
For allperiods:
PF-07321332 and ritonavir will be dosed simultaneously (within no more than 5 minutes 
of each other). Investigator sit e personnel will administer study  intervention during each 
period with ambient temperature water to a total volume of approximately 240 mL. 
Participant s will swallow all tablet formulations whole, and will not manipulate or chew 
the 
study  intervention prior to swallowing. 
In order to standardize the conditions on PK sampling day s, all participant s will be 
required to refrain from ly ing down (except when required for BP, pulse rate , and ECG 
measurements), eating, and drinking beverages other than water duri ng the first [ADDRESS_626172] be stored in a secure, environmentally  controlled, and monitored 
(manual or automated recording) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff. At a 
minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request. Data for nonworking day s must 
indicate the minimum and maximum temperature ssince previousl y documented for 
all site storage locations upon retur n to business .
3.Any excursions from the study  intervention label storage conditions should be 
reported to [COMPANY_007] upon discovery  along with an y actions taken. The site should 
activel y pursue options for returning the stud y intervention to the storage conditi
ons 
described in the labeling, as soon as possible. Once an excursion is identified, the 
study  intervention must be quarantined and not used until [COMPANY_007] provides permission 
to use the study  intervention. Specific details regarding the definition of an exc ursion 
and information the site should report for each excursion will be provided to the site 
in the CRU site procedures.
4.Any storage conditions stated in the SRSD will be superseded by  [CONTACT_78254].
5.Study  interventions
should be stored in their original containers.
6.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y intervention accountability, reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records) , such as the 
IPAL or sponsor -approved equivalent .All study  intervention s will be accounted for 
using a study  intervention accountabilit y form/record.
7.Further guidance and information for the final disposition of unused study  
interventions are provided in the CRU site procedures . All destruction must be 
adequatel y documented. If destruction is authorized to take place at the investigator 
site, the investigator must ensure that the materials are destro yed in compliance with 
applic able environmental regulations, institutional policy , and any  special instructions 
provided b y [COMPANY_007].
Upon identification of a product complaint, notify the sponsor w ithin 1 business day  of 
discovery .

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 346.2.1. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performed to make 
the study  intervention ready  for administration or dispensing to the participant by [CONTACT_216479]. Dispensing is defined as the provision of study  intervention , concomitant treatments, 
and accompan ying information by  [CONTACT_22806](s) to a healthcare provider or 
participant in accordance with this protocol. L ocal health authority  regulations or investigator 
site guidelines may  use alternative terms for these activities.
PF-07321332 150 mg and ritonavir 100 mg tablets
will be prepared at the CRU in the 
individual dosing containers b y 2operators, 1 of whom is an appropriatel y qualified and 
experienced member of the study  staff (eg, physician, nurse, phy sician’s assistant, nurse 
practitioner, pharmacy  assistant/technician, or pharmacist). The tablets will be provided in 
unit dose containers and labeled in accordance with [COMPANY_007] regulations and the clinical site’s 
labeling requirements. 
6.3.Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Study I ntervention
The investigator’s knowledge of the treatment should not influence the decision to enroll a 
particular participant or affect the order in which participant s are enrolled.
The investigator wi ll assign participant numbers to the participant s as they  are screened for 
the study . [COMPANY_007] will provide a randomization schedule to the investigator and, in accordance 
with the randomization numbers, the participant will receive the stud y treatment regim en 
assigned to the corresponding randomization number.
6.4. Study Intervention Compliance
When participants are dosed at the site, they  will receive study  intervention directly  from the 
investigator or designee, under medical supervision. The date and time of e ach dose 
administered in the clinic will be recorded in the source documents and recorded in the CRF.  
The dose of stud y intervention and study participant identification will be confirmed at the 
time of dosing b y a member of the stud y site staff other tha n the person administering the 
study  intervention. Study site personnel will examine each participant’s mouth to ensure that 
the study  intervention was ingested.
6.5. Dose Modification
No dose modification is anticipated. 
6.6.Continued Access to Study Intervention A fter the End of the Study
No intervention will be provided to study  participants at the end of their study  participation.
6.7.Treatment of Overdose
For this study , any  dose of PF -07321332 greater than 2250 mg or ritonavir greater than 
200mgwithin a 24 -hour time period (±2 hours )will be considered an overdose.

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 35There is no specific treatment for an overdose.
In the event of an overdose, the investigator should:
1.Contact [CONTACT_22840] 24 hours.
2.Closely  monitor the participant for an y AEs/SAEs and laboratory  abnormalities for at 
least 5 half -lives or 28 calendar day s after the overdose of PF -07321332/ritonavir
(whichever is longer).
3.Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
4.Overdose is reportable to [COMPANY_007] Safety  only when associated with an SAE.
5.Obtain a blood sample for PK anal ysis within 1day from the date of the last dose of 
study  intervention if requested by  [CONTACT_7195] (determined on a case -by-case 
basis).
Decisions 
regarding dose interruptions or modifications will be made by  [CONTACT_78256].
6.8.Concomitant Therapy
Participants will abstain from all concomitant treatments, exce pt for the treatment of adverse
events and hormonal contraceptives that meet the requirements of this study  in participants 
who are WOCBP (see Appendix 4 ).
Use of prescription or nonprescription drugs and dietary  and herbal supplements are 
prohibited within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention. L imited use of nonprescription medications that are not believed to affect 
participant safety or the overall re sults of the study may  be permitted on a case -by-case basis 
following approval b y the sponsor .Acetaminophen/paracetamol may  be used at doses of 
≤1g/day .
As PF -[ADDRESS_626173]. Additionally , ritonavir and PF -07321332 
are inhibitors of CYP3A4. Therefore, medications highl y dependent on CYP3A4 for 
clearanc e and for which elevated plasma concentrations may  be associated with serious 
and/or life -threatening events are not permitted during dosing of PF- 07321332/ritonavir , 
through [ADDRESS_626174] dose of PF -07321332/ritonavir . 
All concomitant treatments taken during the study  must be recorded with indication, daily  
dose, and start and stop dates of administration. All participants will be questioned about 
concomitant treatment at each clinic visit.

PF-[ADDRESS_626175] dose of study  intervention 
will be documented as concomitant treatments.
6.8.1. Rescue Medicine 
There is no rescue therapy to reverse the A Es observed with PF -07321332 o r ritonavir ; 
standard medical supportive care must be provided to manage the A Es. 
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
It may  be necessary  for a participant to permanently  discontinue study  intervention .Reasons 
for permanent discontinuation of study  intervention include the following.
AE requiring discontinuation in investigator’s view;
Pregnancy ;
Positive COVI D
-[ADDRESS_626176].
If study  intervention is permanentl ydiscontinued, the participant will not remain in the study  
for further evalu ation. See the SoA for data to be collected at the time of discontinuation of 
study  intervention.
7.1.1. Potential Cases of Acute Kidney Injury
Abnormal values in SCr concurrent with presence or absence of increase in BUN that meet 
the criteria below, in the absence of other causes of kidney  injury , are considered potential 
cases of acute kidney  injury  and should be considered important medical events. 
An increase of ≥0.3 mg/dL (or ≥26.5 µmol/L ) in SCr level relative to the participant’s own 
baseline measurement should trigger another assessment of SCr as soon as practicall y 
feasible, preferabl y within 48 hours from awareness.
If the second assessment (after the fir st observations of ≥0.3 mg/dL [or ≥26.5 µmol/L ] in SCr 
relative to the participant’s own baseline measurement) is ≥0.4 mg/dL (or ≥35.4 µmol/L ), the 
participant should be discontinued from the stud y and adequate, immediate, supportive 
measures taken to corr ect apparent acute kidney  injury .
Participants should return to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the second assessment confirming abnormal 
SCr result. This evaluation should include laboratory  tests, detailed history , and phy sical 
assessment. In addition to repeating SCr, laboratory tests should include serum BUN, serum 
creatine kinase, and serum electrol ytes (including at a minimum potassium, sodium, 
phosphate/phosphorus, and calcium), in addition to urinary  dipstick, urine microscopic 
examination, and urinary indices. All cases confirmed on repeat testing as meeting the 

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 37laboratory  criteria for acute kidney  injury , with no other cause(s) of laboratory  abnormalities 
identified, should be considered potential cases of drug -induced kidney  injury  irrespective of 
availability  of all the results of the investigations performed to determine etiology  of the 
abnormal SCr. If ≥2healthy  participants are noted to have 2 consecutive SCr results of 
≥0.3 mg/dL (or ≥26.5 µmol/L), an assessment of whether the finding may be considered an 
adverse drug reaction should be undertaken.
7.2.Participant Discontinuation/ Withdrawal F rom the Study
A participant may  withdraw from the study  at an y time at his/her own request. Reasons for 
discontinuatio n from the study  include the following:
Refused further study  procedures ;
Lost to follow -up;
Death ;
Study  terminated by  [CONTACT_3211] ;
Investigator’s decision
;
Pregnancy
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit should 
be conducted
.See the SoA for assessments to be collected at the time of study  
discontinuation and follow- up and for an y further evaluations that need to be completed. 
The early  discontinuation visit applies only  to participa nts who are enrolled/ randomized and 
then are prematurely  withdrawn from the study .Participants should be questioned regarding 
their reason for withdrawal.  
The participant will be permanentl y discontinued from the study intervention and the study  at 
thattime.
If a participant withdraws from the study , he/she may  request destruction of any  remaining 
samples taken and not tested, and t he investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .
If the partic ipant withdraws from the study  and also withdraws consent (see Section 7.2.1) 
for disclosure of future information, no further evaluations should be performed and no 
additional data should be collected. The sponsor may  retain and continue to use any  data 
collected before such withdrawal of consent.
7.2.1. Withdrawal of Consent 
Participant s who request to discontinue receipt of study  intervention will remain in the st udy 
and must continue to be followed for protocol -specified follow -
up procedures. The onl y 

PF-[ADDRESS_626177] 
with him or her or persons previously  authorized by  [CONTACT_487228]. Participant s should notify  the investigator in writing of the decision to withdraw 
consent from future follow -up, whenever possible. The withdrawal of consent should be 
explained in detail in the medical records b y the investigat or, as to whether the withdrawal is 
only from further receipt of study  intervention or also from study  procedures and/or 
posttreatment study  follow -up, and entered on the appropriate CRF page. In the event that 
vital status (whether the participant is aliv e or dead) is being measured, publicly  available 
information should be used to determine vital status only  as appropriatel y directed in 
accordance with local law.
7.3.Lost to Fol lowup 
A participant will be considered lost to follow- up if he or she repeatedl yfails to return for 
scheduled visits and is unable to be contact[INVESTIGATOR_530] b y the study  site.
The following actions must be taken if a participant fails to attend a required study  visit:
The site must attempt to contact [CONTACT_14315] . Counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether the participant wishes to and/or should 
continue in the study ;
Before a parti cipant is deemed lost to follow -up, the invest igator or designee must 
make every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact [CONTACT_14386] s hould be documented 
in the participant’s medical record ;
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
8.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing an y stud y-specific procedures.  
Study  procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Safety  issues shoul d be discussed with the sponsor immediately  upon occurrence or 
awareness to determine whether the participant should continue or discontinue study  
intervention.
Adherence to the stud
y design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.

PF-[ADDRESS_626178] reasons for 
screening failure, as applicable.
Participants will be screened within 28 days prior to administration of the study  intervention 
to confirm that they  meet the study  population criteria fo r the study . If the time between 
screening and dosing exceeds 28 days as a result of unexpected delay s (eg, delay ed drug 
shipment), then participants do not require rescreening if the laboratory  results obtained prior 
to first dose administration meet elig ibility  criteria.
Every  effort should be made to ensure that protocol -required tests and procedures are 
completed as described. However, it is anticipated that from time to time there may  be 
circumstances outside the control of the investigator that may  make it unfeasible to perform 
the test. I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-being of the participant. When a protocol -required test cannot be performed, the 
investigator will document the reason for th e missed test and an y corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible. The study  team must be informed of these incidents in a timely  manner.
Ifan IV catheter is utilized for blood sample collections, ECGs and vital sign assessments 
(pulse rate andBP) should be collected prior to the insertion of the catheter .
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact [CONTACT_19987] .
The total blood sampling volume for individual participant s in this study  is approximately  
160 mL . The actual collection times of blood sampling may  change. Add itional blood 
samples may  be taken for safet y assessments at times specified b y [COMPANY_007], provided the total 
volume taken during the study  does not exceed 550 mL during an y period of 56 consecutive 
days.
To prepare for stud y participation, participant s will be instructed on the information in the 
Protocol Section 5.3 Lifesty le Considerations and Section 6.8 Concomitant Therap y.
8.1.Efficacy Assessments
Not applicable.
8.2.Safety Asse ssments
Planned time points for all safety  assessments are provided in the SoA .Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  issues.

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 408.2.1. Physical Examinations
A complete physical examination will include , at a minimum, head, ears, eyes, nose, mouth, 
skin, heart and lung examinations, ly mph nodes, and gastrointestinal, musculoskeletal, and 
neurological s ystems. 
A brief physical examination will include, at a minimum, assessments of general appearance, 
the respi[INVESTIGATOR_2866] s ystems, and participant -reported s ymptoms.
Physical examinations may  be conducted by  a ph ysician, trained ph ysician ’s assistant, or 
nurse practitioner as acceptable according to lo cal regulation. 
Height and weight will also be measured and recorded as per the SoA. For measuring weight, 
a scale with appropriate range and resolution is used and must be placed on a stable, flat 
surface. Participant s must remove shoes, bulky  layers of clothing, and jackets so that only  
light clothing remains. They  must also remove the contents of their pockets and remain still 
during measurement of weight. 
Physical examination findings collected during the study  will be considere d source data and 
will not be required to be reported, unless otherwise noted. An y untoward physical 
examination findings that are identified during the active collection period and meet the 
definition of an AE or SAE ( Appendix 3 ) must be reported according to the processes in 
Sections 8.3.1 to 8.3.3.
8.2.2. Vital Signs
Supi[INVESTIGATOR_78235] ’s arm supported at the level of the heart and 
recorded to the nearest mm Hg after approximately [ADDRESS_626179]. The same arm 
(preferabl y the dominant arm) will be used throughout the study
. Participant s should be 
instructed not to speak during measurem
ents.
The same properl y sized and calibrated BP cuff will be used to measure BP each time. The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when 
done manuall y, pulse rate will be measured in the brachial/radial artery  for at least 
30seconds. When the timing of these measurements coincides with a blood collection, BP 
and pulse rate should be obtained prior to the nominal time of the blood collection.
Additional collection times, or changes to collection times, of BP an d pulse rate will be 
permitted, as necessary
, to ensure appropriate collection of safety  data.
[IP_ADDRESS]. Respi[INVESTIGATOR_487220]  5minutes of rest in a supi[INVESTIGATOR_487221] p articipant for [ADDRESS_626180] and before BP measurement.

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Temperature 
Temperature will be measured orall y. No eating, drinking, or smoking is allowed for 
[ADDRESS_626181] 12-l ead ECGs utilizing limb leads (with a 10 second rh ythm strip) should be 
collected at times specified in t he SoA section of this protocol using an ECG machine that 
automatically  calculates the heart rate and measures PR, QT, and QTc intervals and QRS 
complex . Alternative lead placement methodology using torso leads (eg, Mason- Likar) 
should not be used given the potential risk of discrepancies with ECGs acquired using 
standard limb lead placement. All scheduled ECGs should be performed after the participant
has rested quietl y for at least 5 minutes in a supi[INVESTIGATOR_2547]. 
To ensure safe ty of the participants, a qualified individual at the investigator site will make 
comparisons to baseline (Period 1, Day  1) measurements. Additional ECG monitoring will 
occur if a) a postdose QTcF interval is increased by  ≥60 msec from the baseline andis 
>450 msec; or b) an absolute QT value is ≥[ADDRESS_626182] hourl y 
until QTc values from 2 successive ECGs fall below the threshold value that triggered the 
repeat measurement.
If a) a postdose QTc Finterval remains ≥60msecfrom the baseline andis >450 msec; or b) 
an absolute QT value is ≥500 msecfor an y scheduled ECG for greater than 4 hours (or 
sooner, at the discretion of the investigator) ;or c) QTcFintervals get progressively longer, 
the participant should undergo continuous ECG monitoring. A cardiologist should be 
consulted if QTc F intervals do not return to less than the criteri alisted above after 8 hours of 
monitoring (or sooner, at the discretion of the investigator).
In some cases, it may  be a ppropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads beplaced in the 
same positions each time in order to achieve precise ECG recordings. If a machine -read QTc 
value is prolonged, as defined above, repeat measurements may  not be necessary  if a 
qualified medical provider’s interpretation determines that the QTcF values are in the 
acceptable range.
ECG values of potential clinical concern arelisted in Appendix 7.
8.2.4. Clinical Safety Laboratory Assessments
See Appendix [ADDRESS_626183] any  
clinically  relevant changes occurring during the study  in the AE section of the CRF. 
Clinically  significant abnormal laboratory  findings are those which are not associated with 
the underl ying disease, unless judged by  [CONTACT_78259] ’s condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within [ADDRESS_626184] dose of stud y intervention should 
be repeated until the values return to normal or baseline or are no longer considered clinicall y 
significant b y the inv estigator or medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonable by  
[CONTACT_093], the etiology  should be identified and the sponsor notified.
See Appendix 6for suggested actions and follow -
up assessments in the event of potential 
drug-induced liver injury.
Urine drug (mandatory ) and alcohol breath test (at discretion of investigator) will be
performed at screening and on Day  -1. These tests may  be performed at any other time at the
discretion of the investigator.
8.2.5. COVID -
[ADDRESS_626185] will be performed after 4 day s (ie, upon completion of 4 x 24 
hours in house), or if they develop COVID -[ADDRESS_626186] 
25mIU/mL. Pregnancy  tests will be performed in WOCBP at the times li sted in the SoA .  
Following a negative pregnancy  test result at screening, appropriate contraception must be 
commenced and a second negative pregnancy test result will be required at the baseline visit 
prior the participant ’sreceiving the study  intervention . Pregnancy  tests will also be done 
whenever 1 menstrual cycle is missed during the active treatment period (or when potential 
pregnancy  is otherwise suspected) and at the end of the study . Pregnancy  tests may  also be 
repeated if r equested by  [CONTACT_1202]/E Cs or if required by [CONTACT_427]. If a urine test cannot be 
confirmed as negative (eg, an ambiguous result), a serum pregnancy  test is required. In such 
cases, the participant must be excluded if the serum pregnancy  result is positi ve.

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 438.3.Adverse Events ,Serious Adverse Events , and Other Safety Reporting
The definitions of an AE and an SAE can be found in Appendix 3.
AEs may  arise from s ymptoms or other complaints reported to the investigator by  [CONTACT_2416] (or, when appropriate, b y a caregiver, surrogate, or the participant ’s legally  
authorized representative), or they  may  arise from clinical findings of the Investigator or 
other healthcare providers (clinical signs, test results, etc.).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
thestudy  interventio n(seeSection 7.1). 
During the active collection period as described in Section 8.3.1, e ach participant will be 
questioned about the occurrence of A Es in a nonleading manner.
In addition, the investigator may  be requested by  [CONTACT_19989] y to obtain specific follow -
up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for C ollecting AE and SAE Information
The time period for actively  eliciting and collecting A Es and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant ’s participation in the study  (ie, before undergoing 
any study -related procedure and/or receiving study  intervention ), through and including a 
minimum of [ADDRESS_626187] SAE Report Form.
Investigators are not obligated to activel y seek information on AEs or SAE safter the 
participant has concluded study  participation . However, if the investigator learns of an y SAE, 
including a death, at an y time after a participant has completed the study , and he/she 

PF-[ADDRESS_626188] SAE Report Form.
[IP_ADDRESS].
Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.3.[ADDRESS_626189] SAE Report Form immediately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3. The investigator will submit any  updated SAE data to the sponsor within 
24 hours of it being available.
[IP_ADDRESS]. Recording Nonserious A Es and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.3.[ADDRESS_626190] to the CRF 
requirements as described in Section 5.4.
8.3.2.
Method of Detecting AE s and SAEs
The method of recording, evaluating, and assessing causality  of A Esand SAE sand the 
procedures for completing and transmitting SAE reports are provided in Appendix 3.
Care will be taken not to introduce bias when detecting A Es and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -
Up of A Es and SAEs
After the initial AE or SAE report, the investigator is required to proactively  follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality . Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided. In the case of a participant death, a summary  of available 
autopsy  findings must be submitted as soon as possible to [COMPANY_007] Safety . 
Further information on follow -up procedures is given in Appendix 3.

PF-[ADDRESS_626191] the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulato ry authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRBs/ECs, and investigators.
Investigator safety  reports must be prepared for S[LOCATION_003]R saccording to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives S[LOCATION_003]Rs or other specific safet y information (eg, summary  or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study and will notify  the IRB/EC, if appropriate according to local requirements.
8.3.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, a nd 
Occupational Exposure
Environmental exposure occurs when a person not enrolled in the study  as a participant 
receives unplanned direct contact [CONTACT_216480]. Such exposure 
may or may  not lead to the occurrence of an AE or SA E. Persons at risk for environmental 
exposure include healthcare providers, famil y members, and others who may be exposed. An 
environmental exposure may  include exposure during pregnancy , exposure during 
breastfeeding, and occupational exposure.
Any such e xposure to the study  intervention under study  are reportable to [COMPANY_007] Safet y 
within 24 hours of investigator awareness.
[IP_ADDRESS]. Exposure During Pregnancy
An EDP occurs if:
A female participant is found to be pregnant while receiving or after discontinuing 
study  intervention.
A male participant who is receiving or has discontinued study  intervention exposes a 
female partner prior to or around the time of conception .
A female is found to be pregnant while being exposed or having been exposed to 
study  intervention due to environmental exposure. Below are examples of 
environmental EDP :  
A female family  member or healthcare provider reports that she is pregnant after 
having been exposed to the study  intervention by  [CONTACT_78262] .

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 46A male famil y member or healthcare provider who has been exposed to the study  
intervention by  [CONTACT_78263] .
The investigator mus t report EDP to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery  (see below for information related to 
termination 
of pregnancy). 
If EDP occurs in a participant or a participant’s partner, the investigator must report 
this information to [COMPANY_007] Safety on the CT SAE Report Form and an EDP 
Supplemental Form, regardless of whether an SAE has occurred. Details of the 
pregnancy  will be collected after the start of study  intervention and until [ADDRESS_626192] dose.
If EDP occurs in the setting of environmental exposure, the investigator must report 
information to [COMPANY_007] Safety  using the CT SAE Report Form and EDP Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study , the information is not recorded on a CRF; however, a copy  of the 
completed CT SAE Report Form is maintained in the investigator site file.
Follow -upis conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  [COMPANY_007] Safet y of the outcome a sa 
follow -up to the initial EDP S upplemental Form. In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth. In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by [CONTACT_4692] (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
Abnormal pregnancy  outcomes are c onsidered SAEs. If the outcome of the pregnancy  meets 
the criteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y in a live -born bab y, a terminated fetus, an 
intrauterine fetal demi se, or a neonatal death), the investigator should follow the procedures 
for reporting SAEs. Additional information about pregnancy  outcomes that are reported to 
[COMPANY_007] Safety  as SAEs follows: 
Spontaneous abortion includ ingmiscarriage and missed abortion;
Neonatal deaths that occur within [ADDRESS_626193] 
to causality , as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the study  intervention. 

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 47Additional information regarding the EDP may  be requested by  [CONTACT_456]. Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s). In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner. The investigator must document in the source documents that 
the participant was given the P regnant Partner Release of Information Form to provide to his 
partner.
[IP_ADDRESS]. Exposure During Breastfeeding
An exposure during breastfeeding occurs if: 
A female participant is found to be breastfeeding while receiving or after 
discontinuing study  intervention .
A female is found to be breastfeeding while being exposed or having been exposed to 
study  intervention (ie, environmental exposure). An example of environmental 
exposure during breastfeeding is a female family  member or healthcare provider who 
reports that she is breastfeeding after having been exposed to the study  intervention 
by [CONTACT_78262] .  
The investigator must report exposure during breastfeeding to [COMPANY_007] Safety  within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurre d. The 
information must be reported using the CT SAE Report Form. When exposure during 
breastfeeding occurs in the setting of environmental exposure, the exposure information does 
not pertain to the participant enrolled in the stud
y, so the information is not recorded on a 
CRF. However, a cop y of the completed CT SAE Report Form is maintained in the 
investigator site file.
An exposure during breastfeeding report is not created when a [COMPANY_007] drug specificall y 
approved for use in breastfeeding women (eg, vita
mins) is administered in accord with 
authorized use. However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure during breastfeeding.
[IP_ADDRESS]. Occupational Exposure
The investigator must report any  instance of occupational exposure to [COMPANY_007] Safet y within 24 
hours of the investigator’s awareness 
using the CT SAE Report Form regardless of whether 
there is an associated SAE. Since the information about the occupational exposure does not 
pertain to a participan tenrolled in the study , the information is not recorded on a CRF; 
however, a cop y of the completed CT SAE Report Form must be maintained in the 
investigator site file .
8.3.6. Cardiovascular and Death Events
Not applicable .

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 488.3.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as A Es 
or SAEs
Not applicable .
8.3.8. Adverse Events of Special Interest
Adverse events of special interest (AESIs) are examined as part of routine safet y data review 
procedures throughout the clinical trial and as part of signal de tection processes.
All AESI s must be reported as an AE or SAE following the procedures described in 
Section 8.3.[ADDRESS_626194] SAE Report Form.
[IP_ADDRESS]. Lack of Efficacy
This section is not applicable because efficacy  is not expected in the study  population.
8.3.9. Medical Device Deficiencies
Not applicable .
8.3.10. Medication Errors
Medication errors may  result from the administration or consumption of the study  
intervention by [CONTACT_19995] , or at the wrong time, or at the wrong dosage strength.
Exposures to the study  intervention under stud y may occur in clinical trial settings, such as 
medication errors.
Safety Event Recorded on the CRF Reported on the CT SAE Report 
Form to [COMPANY_007] Safety Within 
24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE
Medication errors include:
Medication errors involving participant exposure to the study  intervention ;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the studyparticipant .
Such medication errors occurring to a stud
y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within 24 hours .

PF-07321332 
Protocol C4671019Final Protocol, 18 October 2021
PFIZER CONFIDENTIAL
Page 49Whether or not the medication error is accompanied by [CONTACT_1149], as determined by [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if applicable, any associated AE(s), serious and nonserious, are recorded on the AE page of the CRF.
Medication errors should be reported to [COMPANY_007] Safety within [ADDRESS_626195] SAE Report 
Form only when associated with an SAE.
8.4. Pharmacokinetics
8.4.1. Plasma for Analysis of PF-07321332Blood samples of approximately 4 mL, to provide approximately 1.5 mL plasma, will be 
collected for measurement of plasma concentrations of PF-07321332 as specified in the SoA. 
Instructions for the collection and handling of biological samples will be provided in the laboratory manual or by [CONTACT_456]. The actual date and time (24-hour clock time) of each sample will be recorded.
The actual times may change, but the number of samples will remain the same. All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing. Collection of samples up to and including 10 hours after dose administration that are obtained within 10% of the nominal time relative to dosing (eg, within 6 minutes of a 60-minute sample) will not be captured as a protocol deviation, as long as the exact time of the collection is noted on the source document and the CRF. Collection of samples more than 10 hours after doseadministration that are obtained ≤[ADDRESS_626196] time of the collection is noted on the source document and the CRF. 
Samples will be used to evaluate the PK of PF-07321332. Samples collected for analyses of 
plasma PF-07321332 concentration may also be used to evaluate safety or efficacy aspects related to concerns arising during or after the study, for metabolite identification and/or evaluation of the bioanalytical method, 
 
Samples collected for measurement of plasma concentrations of PF-[ADDRESS_626197] be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity. Any deviations from the PK sample handling procedure (eg, sample collection and processing steps, interim storage or shippi[INVESTIGATOR_19944]), including any actions taken, must be documented and reported to the sponsor.  On a case-by-case basis, the sponsor may make a determination as to whether sample integrity has been compromised.
CCI
CCI
PF-[ADDRESS_626198] 
be documented and approved by [CONTACT_487229], but will not constitute a protocol amendment. The IRB/EC will be informed of any safety issues that require alteration of the safety monitoring scheme or amendment of the ICD.
 
 
 
 
  CCI
PF-07321332 
Protocol C4671019Final Protocol, 18 October 2021
PFIZER CONFIDENTIAL
Page 51 
 
 
 
8.7. Immunogenicity Assessments
Immunogenicity assessments are not included in this study.
8.8. Health Economics
Health economics/medical resource utilization and health economics parameters are not 
evaluated in this study.
9. STATISTICAL CONSIDERATIONS
Detailed methodology for summary and statistical analyses of the data collected in this study 
is outlined here and further detailed in a SAP, which will be maintained by [CONTACT_456]. The SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment.
9.1. Statistical Hypotheses
No statistical hypothesis will be tested in this study. 
9.2. Analysis Sets
For purposes of analysis, the following analysis sets are defined:
Participant Analysis 
SetDescription
Enrolled/Randomly 
assigned to study intervention“Enrolled” means a participant’s, agreement to participate in a 
clinical study following completion of the informed consent process and screening. Potential participants who are screened for the purpose of determining eligibility for the study, but do not participate in the study, are not considered enrolled, unless otherwise specified by [CONTACT_760]. A participant will be considered enrolled if the informed consent is not withdrawn prior to participating in any study activity after screening.
Safety Analysis Set All participants randomly assigned to study intervention and 
who take at least [ADDRESS_626199] are reported .
9.3. Statistical Analyses
The SAP will be developed and finalized before any anal yses are pe rformed and will 
describe the anal yses and procedures for accounting for missing, unused, and spurious data. 
This section is a summary of the planned statistical analy ses of the primary  and secondary  
endpoints.
9.3.1. Primary Endpoint(s)
[IP_ADDRESS]. D erivation of Pharmacokinetic Parameters
Plasma PK parameters of PF-07321332 will be derived (as data permit) from the 
concentration -time data using standard noncompartmental methods as outlined in the 
Table 2. Actual PK sampling times will be used in the derivation of PK parameters. In the 
case that actual PK sampling times are not available, nominal PK sampling time will be used 
in the derivation of PK parameters. 

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 53Table 2. Plasma PF -07321332 PK Parameters Definitions 
Param eter Definition Method of Determ ination
AUC inf* Area under the plasma concentration -time curve 
from time zero extrapolated to infinityAUC last+ (C last*/k el),
where C last* is the predicted plasma 
concentration at the last quantifiable 
time point from the log -linear 
regression analysis
AUC last Area under the plasma concentration -time profile 
from time zero to the time of the last quantifiable 
concentration (C last).Linear/Log trapezoidal method.
Cmax Maximum observed plasma concentration Observed directly from data
Tmax Time to reach Cmax Observed directly from data as time of 
first occurrence
t½* Term inal elimination half-life Log e(2)/k el,
where k elis the terminal phase rate 
constant calculated by a linear 
regression of the loglinear 
concentration -time curve. Only those 
data points judged to describe the 
terminal loglinear decline will be used 
in the regression.
CL/F * Apparent clearance Dose/AUC inf
Vz/F* Apparent volume of distribution for extravascular 
dosingDose/(AUC inf• kel)
*If data permit.
[IP_ADDRESS]. S tatistical Methods for P harmacokinetic Data
Natural log transformed AUC inf(if data permit), AUC lastand C maxwill be anal yzed using a 
mixed effect model with sequence, period and treatment as fixed effects and participant 
within sequence as a random effect. Estimates of the adjusted mean differences (Test -
Reference) and corresponding 90% CIs will be obtained fro m the model. The adjusted mean 
differences and 90% CIs for the differences will be exponentiated to provide estimates of the 
ratio of adjusted geometric means (Test/Reference) and 90% CI for the ratios. Treatment A 
(PF-07321332/ritonavir administered under fasted condition) is the Reference treatment and 
Treatment B (PF -07321332/ritonavir administered under fedcondition) is the Test treatment. 
The plasma concentrations of PF- 07321332 will be listed and descriptivel y summarized by  
[CONTACT_273480]. Individual participant, as well as mean and median 
profiles of the plasma concentration time data will be plotted by  [CONTACT_219895] (for 
individual) and nominal (for mean and median) times respectivel y. Mean and median profiles 
will be presented on both linear and semi -log scales. 
The PK parameters listed in Table 2will be summarized descriptivel y by [CONTACT_3148].
Additional specifications about the tables, listings, and figures will be outlined in the SAP.

PF-07321332 
Protocol C4671019Final Protocol, 18 October 2021
PFIZER CONFIDENTIAL
Page 549.3.2. Other Safety Analyses
All safety analyses will be performed on the safety population.
Safety data will be presented in tabular and/or graphical format and summarized 
descriptively, where appropriate.
Medical history and physical examination and neurological examination information, as 
applicable, collected during the course of the study will be considered source data and will not be required to be reported, unless otherwise noted. However, any untoward findings identified on physical and/or neurological examinations conducted during the active collection period will be captured as AEs, if those findings meet the definition of an AE.  Data collected at screening that are used for inclusion/exclusion criteria, such as laboratory data, ECGs, and vital signs, will be considered source data, and will not be required to be reported, unless otherwise noted. Demographic data collected at screening will be reported.
 
9.4. Interim Analyses
No formal interim analysis will be conducted for this study. As this is an open-label
study, the sponsor may conduct unblinded reviews of the data during the course of the study for the purpose of safety assessment, facilitating PK/PD modeling, and/or supporting clinical development. 
9.5. Sample Size Determination
Approximately 12 participants will be enrolled in the study. Participants who withdraw from 
the study may be replaced at the sponsor’s discretion in collaboration with the Investigator.
 
 
 
 
 
 CCI
CCI
CCI
PF-07321332 
Protocol C4671019Final Protocol, 18 October 2021
PFIZER CONFIDENTIAL
Page 55 CCI
PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 5610.SUPPORTING DOCUMENTATION AND OP ERATIONAL CONSIDERAT IONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines, including the 
Declaration of Helsinki and CI OMS International Ethical Guidelines ;
Applicable ICH GCP guidelines;
Applicable laws and regulations , including applicable privacy  laws .
The protocol, protocol am endments, I CD, SRSD(s) , and other relevant documents 
(eg,advertisements) must be 
reviewed and approved by  [CONTACT_456] ,submitted to an I RB/EC 
by [CONTACT_093], and reviewed and approved by  [CONTACT_1201]/EC before the study  is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
Protocols and an y substantial amendments to the protocol will require hea lth authority  
approval prior to initiation except for changes necessary to eliminate an immediate hazard to 
study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
[CONTACT_1744]/EC procedures;
Providing oversight of the conduct of the study  at the site and adherence to 
requirements of 21 CFR, ICH GCP guidelines, the I RB/EC, European regulation 
536/2014 for clinical studies (if applicable), European Medical Device Regulation 
2017/745 for clinical device research (if applicable), and all other applicable local 
regulations .
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the study  
intervention , [COMPANY_007] should be informed immediately .  

PF-[ADDRESS_626200], and 
of an y serious breaches of this protocol or of the ICH GCP guidelines that the investigator 
becomes aware of.
10.1.2. Informed Consent Process
The investiga tor or his/her representative will explain the nature of the study , including the 
risks and benefits, to the participant and answer all questions regarding the study .The 
participant should be given sufficient time and opportunity  to ask questions and to decide 
whether or not to participate in the trial.
Participants must be informed that their participation is voluntary . Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, 
local regulations, ICH gu idelines, privacy  and data protection requirements, where 
applicable, and the IRB/EC or study  center.
The investigator must ensure that each study  participant is fully  informed about the nature 
and objectives of the study, the sharing of data related to th e study ,and possible risks 
associated with participation, including the risks associated with the processing of the 
participant ’s personal data. 
The participant must be informed that his/her personal study -related data will be used by  [CONTACT_51469]. The level of disclosure must also be 
explained to the participant.
The participant must be informed that his/her medical records may  be examined by  [CONTACT_487230], by  
[CONTACT_6667]/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensure that each study  participant is fully  informed about his or 
her right to access and correct his or her personal data an d to withdraw consent for the 
processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and the date on which 
the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the IC D.
Participants must be reconsented to the most current version of the IC D(s) during their 
participation in the study .
A cop y of the IC D(s) must be provided to the participant.
Participants who are rescreened are required to sign a new IC D.

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 5810.1.3. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic and/or paper 
form and will be password -protected or secured in a locked room to ensure that only  
authorized study  staff have access. The study  site will implement a ppropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster. In the event of a potential personal data breach, the study site will be responsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach 
notifications as required by  [CONTACT_2371].
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical c ode. An y 
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  [CONTACT_20007], participant-specific code. The study  site will 
maintain a confidential list of participant s who participated in the study, linking each 
participant ’s numerical code to his or her actual identity and medical record ID. In case of 
data transfer, the sponsor will protect the confidentiality  of participant s’ personal data 
consistent with the c linical study agreement and applicable privacy  laws.
10.1.4. Committees Structure
[IP_ADDRESS]. Data Monitoring Committee 
This study  will not use a DMC.
10.1.5. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer .com, and other public registries in accordance with applicable local 
laws/regulations. In addition, [COMPANY_007] reports study  results outside of the requirements of local 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and ar e reported regardless of the outcome of the study  or the country  in 
which the study  was conducted.
www.clinicaltrials .gov
[COMPANY_007] posts clinical trial results on www.clinicaltrials.gov for [COMPANY_007]- sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which the study  is conducted. These r esults are 
submitted for posting in accordance with the format and timelines set forth by  [CONTACT_20008].

PF-[ADDRESS_626201] for [COMPANY_007] -sponsored interventional studies in 
accordance with the format and timelines set forth by  [CONTACT_20009].
www.pfizer .com
[COMPANY_007] posts public disclosure s ynopses (CSR synopses in which an y data that could be used 
to identify  individual participants have been removed) on www.pfizer .com for 
[COMPANY_007] -sponsored interventional studies at the same time the corresponding study  results are
posted to www.clinicaltrials.gov .
Documents within marketing authorization packages/submissions
[COMPANY_007] complies with the European Union Policy  0070, the proactive publication of clinical 
data to the EMA website. Clinical data, under Phase 1 of this policy ,includes clinical 
overviews, clinical summaries, C SRs, and appendices containing the protocol and protocol 
amendments, sample CRF s, 
and statistical methods. Clinical data, under Phase 2 of this 
policy ,includes the publishing of individual participant data. Policy  0070 applies to new 
marketing authorization applications submitted via the ce ntraliz ed procedure since 
01January 2015 and applications for line extensions and for new indications submitted via 
the centralized procedure since 
01 July  2015.
Data sharing
[COMPANY_007] provides researchers secure access to patient- level data or full CSRs for the purposes 
of “bona -fide scientific research” that contribute sto the scientific understanding of the 
disease, target, or compound class. [COMPANY_007] will make data from these trials available 
24months after study  completion. Patient- level data will be anon ymized in accordance with 
applicable privacy  laws and regulations. CSRs will have personally  identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analy ses. Rese arch teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
10.1.6. Data Quality Assurance
All participant data relating to the stud y will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  [CONTACT_20010].
Guidance on completion of CRFs will be provided in the CRF Completion Requirements 
document.

PF-[ADDRESS_626202] ensure that the CRFs are securel y stored at the study site in encrypted 
electronic and/or paper form and ar e password -protected or secured in a locked room to 
prevent access b y unauthorized third parties.
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents. This 
verification may  also occur after study  completion. I t is important that the investigator(s) and 
their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to t he process.
Monitoring details describing strategy , including definition of study  critical data items and 
processes (eg, risk- based initiatives in operations and quality ,such as risk management and 
mitigation strategies and analytical risk-based monitorin g), methods, responsibilities ,and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual , or on- site monitoring) , are provided in the data management plan and/or 
IQMP maintained and utilized by  [CONTACT_36613] .
The sponsor or designee is responsible for the data management of this study ,including 
quality  checking of the data.
Records and documents, including signed IC Ds, pertaining to the conduct of this study  must 
be retained b y the investigator for 15years after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the sponsor. No records may  be 
transferred to anot her location or part y without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored securel y for aslong as they  are 
maintained.
When participant data are to be deleted, the investigator will ensure that a ll copi[INVESTIGATOR_78245] y deleted from all systems.
The investigator(s) will notify  the sponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study
. Furthermore, the investigator will coope rate 
with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly  resolve any  discre pancies that are identified 
between the stud y data and the participant ’s medical records. The investigator will promptly  
provide copi[INVESTIGATOR_19946]. Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings.
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the dat a collected. Source documents are filed at the investigator site.

PF-[ADDRESS_626203] be available.
Definition of what constitutes source data and its origin can be found in the Source 
Document Locator , which is maintained by  [CONTACT_456] ’s designee ([COMPANY_007] Clinical Research 
Unit) .
Description 
ofthe use of the computerized sy stem is documented in the Source Document 
Locator , which is maintained by  [CONTACT_456] ’s designee ([COMPANY_007] Clinical Research Unit) .
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study  is 
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP guidelines, and all applicabl e regulatory  requirements.
10.1.8. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruitment of 
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study  
start date.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor. Study  sites will be closed upon study  
completion. A study  site is considered c losed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon notification to the sponsor if 
requested to do so b y the responsible IRB/EC or if such termination is required to protect the 
health of study  participants.
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirem ents of the 
IRB/EC or local health authorities, the sponsor ’s procedures, or the ICH GCP 
guidelines ;
Inadequate recruitment of participants by  [CONTACT_093];
Discontinuation of further study  intervention development .

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 62If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the E Cs/IRBs, the regulatory  authorities, and any  CRO (s) used in the study  of 
the reason for termination or suspension, as specified by  [CONTACT_20013]. The investigator shall promptly  inform the participant and should assure 
appropriate 
participant therapy  and/or follow -up.
Study  term ination is also provided for in the clinical study  agreement. If there is any  conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.9. Publication Policy
The results of this study  may  be published or presented at scientific meetings b y the 
investigator after publication of the overall study  results or 1year after the end of the stud y 
(or study  termination), whichever comes first. 
The investigator agrees to refer to the primary  publication in any  subsequent publi cations,
such as secondary manuscripts, and submit s all manuscripts or abstracts to the sponsor 
30days before submission. This allows the sponsor to protect proprietary  information and to 
provide comments , and the investigator will, on request, remove any previously  undisclosed 
confidential information before disclosure, except for an y stud y-or [COMPANY_007] -intervention 
related information necessary  for the appropriate scientific presentation or understanding of 
the study  results.
For all publications relating to the study , the investigator will compl y with recognized ethical 
standards concerning publications and authorship, including those established by  [CONTACT_19483].
The sponsor will comply  with the requirements for pu blication of the over all study  results 
covering all i nvestigator sites. In accordance with standard editorial and ethical practice, the 
sponsor will support publication of multicenter studies only  in their entirety and not as 
individual site data. In this case, a coordinating investigator [INVESTIGATOR_159828] b y mutual 
agreement.
Authorship of publications for the overall study  results will be determined by  [CONTACT_78275] I nternational Committee of Medical Journal Editors authorship 
require ments. 
If publication is addressed in the clinical study  agreement, the publication policy  set out in 
this section will not apply.
10.1.10. Sponsor’s Qualified Medical Personnel
The contact [CONTACT_1133] ’s appropriately  qualified medical personnel for the 
study  is documented in the study  contact [CONTACT_306925] . 
To facilitate access to appropriatel y qualified medical personnel for study -related medical 
questions or problems, participants are provided with an Emergency  Contact [CONTACT_74057] (ECC) at
the time of informed consent. The ECC contains, at a minimum, (a) protocol and study  

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 63intervention identifiers, (b) participant’s stud y identification number, (c) site emergency 
phone number active 24 hours/day , [ADDRESS_626204] s 
between the investigator, site staff, and study  team. The ECC is to be used by  [CONTACT_78277] y only , as a means of reaching the investigator 
or site staff related to the care of a participant. 

PF-07321332 
Protocol C4671019Final Protocol, 18 October 2021
PFIZER CONFIDENTIAL
Page 6410.2. Appendix 2: Clinical Laboratory Tests
The following safety laboratory tests will be performed at times defined in the SoA section of 
this protocol. Additional laboratory results may be reported on these samples as a result of the method of analysis or the type of analyzer used by [CONTACT_20019], or as derived from calculated values. These additional tests would not require additional collection of blood. Unscheduled clinical laboratory measurements may be obtained at any time during the study to assess any perceived safety issues.
Table 3. Protocol-Required Safety Laboratory Assessments
Hematology Chemistry Urinalysis Other
Hemoglobin
Hematocrit
RBC count
MCVMCHMCHCPlatelet countWBC count
Total neutrophils (Abs)
Eosinophils (Abs)Monocytes (Abs)Basophils (Abs)Lymphocytes (Abs)BUN and creatinine
Glucose (fasting)
Calcium
SodiumPotassiumChlorideTotal CO
2(bicarbonate)
AST, ALT
Total bilirubin
Alkaline phosphataseUric acidAlbuminTotal proteinLocal Dipstick:
pH
Glucose (qual)
Protein (qual)Blood (qual)KetonesNitritesLeukocyte esterase
Laboratory:
Microscopy and 
Culturea•SARS-CoV-2 RT-PCR
•Urine drug screeningc
•Pregnancy test ( β-hCG)d
•eGFR [CKD-EPI]
Coagulation:
•aPTT
•PT-INR
•Fibrinogen
At screening only:
•FSHb
•HBsAg
•HBsAbe
•HBcAb
•HCVAb
•HIV
a. Only if urine dipstick is positive for blood, protein, nitrites, or leukocyte esterase and culture only if 
bacteriuria.
b. For confirmation of postmenopausal status only.c. The minimum requirement for drug screening includes cocaine, THC, opi[INVESTIGATOR_858]/opi[INVESTIGATOR_2438], benzodiazepi[INVESTIGATOR_1651], 
and amphetamines (others are site and study specific).
d. Local urine testing will be standard for the protocol unless serum testing is required by [CONTACT_112249]/EC. Serum β-hCG for female participants of childbearing potential.
e. HBsAb will be tested if HBsAg and/or HBcA bare positive.
The investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the CRF.
Any remaining serum/plasma from samples collected for clinical safety laboratory 
measurements at baseline and at all times after dose administration may be retained and stored for the duration of the study.
 
These data will not be included in the CSR. Samples to be used for this 
purpose will be shipped to either a [COMPANY_007]-approved BBS facility or other designated laboratory and retained for up to 1 year following the completion of the study.CCI
PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 6510.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study 
participant, temporally associated with the use of study intervention, whether or 
notconsidered related to the study  intervention.
Note: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) 
temporally associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or 
urinaly sis) or other safety  assessments (eg, ECG, radiological scans, vital sign 
measurements), including those that worsen from baseline, considered clinically  
significant in the medical and scientific judgment of the investigator. Any 
abnormal laboratory  test results that meet any  of the conditions below must be 
recorded as an AE:
Is associated with accompany ing s ymptoms;
Requires additiona l diagnostic testing or medical/surgical intervention;
Leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the study , significant additional 
concomitant drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition, including either 
an increase in frequency  and/or intensity  of the condition.
New condition detected or diagnosed after stud y intervention administration ,
even though it may have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE or SAE unless it is an intentional overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardless of 
sequelae.

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 66Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments that are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The disease/dis order being studied or expected progression, signs, or s ymptoms 
of the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads t o the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) 
present or detected at the start of the study  that do not worsen.
10.3.2. Definition of an SAE
AnSAE is defined as any untoward medical occurrence that, at any dose, meets one 
or more of the criteria listed below:
a.Results in death
b.Is life -threatening
The term “life-threatening ”in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event that hypotheticall y might have caused death if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_12994] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_23917]/or treatment that would not have been appropriate in the phy sician’s 
office or outpatient setting. Complications that occur during hospi[INVESTIGATOR_227926] A Es. 
If a complication prolongs hospi[INVESTIGATOR_23919], the 
event is serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was 
necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen 
from baseline is not considered an AE.

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 67d.Results in persistent or significant disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance , such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle), thatmay interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Is a suspected transmission via a [COMPANY_007] product of an infectious agent, 
pathogenic or non -pathogenic, is considered serious.  
The event may  be suspected from clinical s ymptoms or laboratory  findings 
indicating an infection in a participant exposed to a [COMPANY_007] product. The terms 
“suspected transmission” and “transmission” are considered s ynon ymous. These 
cases are considered unexpected and handled as serious expedited cases b y 
pharmacovigilance personnel. Such cases are also considered for reporting as 
product defects, if appropri ate.
g.Other situations:
Medical or scientific judgment should be exercised by [CONTACT_216484] ,such as 
significant medical events that may  jeopardize the participant or may  require 
medical or surgical intervention to prevent one of the other outcomes listed in the 
above definition. These events should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], or development of 
drug dependency  or drug abuse.
10.3.3. Recording/Reporting and Follow -Up of A Esand/or SAE sDuring the Active 
Collection Period
AE and SAE Recording /Reporting
The table below summarizes the requirements for recording AEs on the CRF and for 
reporting SAEs on the CT SAE Report Form to [COMPANY_007] Safet ythroughout the active 
collection period . These requirements are delineated for 3 ty pes of ev ents: (1) SAEs; (2) 
nonserious A Es; and (3) exposure to the study  intervention under stud y during 
pregnancy  or breastfeeding, and occupational exposure. 

PF-[ADDRESS_626205] SAE 
Report Form to [COMPANY_007] 
Safety Within 24 Hours 
of Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeedingAll A Es/SAEs associated 
with exposure during 
pregnancy  or breastfeeding
Note: Instances of EDP or 
EDB not associated with an 
AE or SAE are not captured 
in the CRF.All instances of EDP are 
reported (whether or not 
there is an associated 
SAE)*
All instance s of EDB are 
reported (whether or not 
there is an associated 
SAE).**
Environmental or 
occupational exposure 
to the product under 
study  to a non -
participant (not 
involving EDP or EDB).None. Exposure to a study 
non-participant is not 
collected on the CRF.The exposure (whether or 
not there is an associated 
AE or SAE) must be 
reported.***
*EDP (with or without an associated AE or SAE): any pregnancy information is reported to 
[COMPANY_007] Safety using CT SAE Report Form and EDP Supplemental Form; if the EDP is associated 
with an SAE, then the SAE is reported to [COMPANY_007] Safety using the CT SAE Report F orm. 
** EDB is reported to [COMPANY_007] Safety using the CT SAE Report Form which w ould also include 
details of any SAE that might be associated w ith the EDB. 
***Environmental or Occupational exposure: AEs or SAEs associated with occupational 
exposure are reported to [COMPANY_007] Safety using the CT SAE Report Form. 
When an AE or SAE occurs, it is the responsibility  of the investigator to review 
all documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE or SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety  in lieu of completion of the CT SAE Report 
Form /AEor SAE CRF p age.

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 69There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_007] Safety .In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_19953] .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis 
(not the individual signs/sy mptoms) will be documented as the AEor SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: Asymptomatic or mild sy mptoms; clinical or diagnostic observations only ; 
intervention not indicated.
Moderate: Minimal, local or noninvasive intervention indicated; limiting age -
appropriate instrumental ADL. Instrumental ADL refers to preparing meals, 
shoppi[INVESTIGATOR_3112], using the telephone, managing money , etc.
Severe: Severe or medically  significant but not imme diately  life-threatening; 
hospi[INVESTIGATOR_3111]; disabling, limiting 
self-care ADL. Self-care ADL refers to bathing, dressing and undressing, feeding 
self, using the toilet, taking medications, and not bedridden.
An e vent is defined as “ serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE or SAE. The investigator will use clinical 
judgment to determine the relationship.
A “reasonable possibility” of a relationship conveys that there are facts, 
evidence, and/or arguments to suggest a causal relatio nship, rather than a 
relationship cannot be ruled out.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration, will be considere d and investigated.
The investigator will also consult the IB and/or product information, for 
marketed products, in his/her assessment.

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 70For each AE or SAE, the investigator must document in the medical notes that 
he/she has reviewed the AE or SAE and has p rovided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assess ment of causality 
for every event before the initial transmission of the SAE data to the 
sponsor .
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send a nSAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  intervention caused the 
event, then the event will be handled as “related to study intervention ” for 
reporting purposes, as defined by  [CONTACT_456] . In addition, if the investigator 
determines that an SAE is associated with study  procedures, the investigator 
must record this causal relationship in the source documents and CRF, and repo rt 
such an assessment in the dedicated section of the CT SAE Report Form and in 
accordance with the SAE reporting requirements.
Follow -Up of A Es and SAEs
The investigator is obligated to perform or arrange for the conduct of 
supplemental measurements and/or evaluations ,as medically  indicated or as 
requested b y the sponsor ,to elucidate the nature and/or causalit y of the AE or 
SAE as fully  as possible. This may  include additional laboratory  tests or 
investigations, histopathological examinations, or co nsultation with other 
healthcare providers .
If a participant dies during participation in the study or during a recognized 
follow -up period, the investigator will provide [COMPANY_007] Safet y with a cop y of any 
postmortem findings
,including histopathology .
New o r updated information will be recorded in the originally  submitted 
documents .
The investigator will submit any  updated SAE data to the sponsor within 24 
hours of receipt of the information.

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 7110.3.4. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety will be the 
electronic data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool (see next s ection) to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as the data
become available.
After the stud y is completed at a given site, the electronic data collection tool 
will be taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives 
updated data on a previously  reported SAE after the electronic data collection 
tool has been taken off -line, then the site can report this information on a paper 
SAE form (see next section) or to [COMPANY_007] Safet y by [CONTACT_756].
SAE Reporting to [COMPANY_007] Safety via CT SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to [COMPANY_007] Safety .
In circumstances when the facsimile is not working , notification by  [CONTACT_20021] a cop y of the CT SAE Report Form sent by  [CONTACT_20022].
Initial not ification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designated 
reporting time frames.

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 7210.4. Appendix 4: Contraceptive and Barrier Guidance
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they  agree to the following requirements during 
the intervention period and for at least 28days after the last dose of study  intervention ,which 
corresponds to the time needed to eliminate reproductive safet y risk of the study  
intervention(s): 
Refrain from donating sperm.
PLUS either :
Be abstinent from heterosexual intercourse with a female of childbearing potential as 
their preferred and u sual lifesty le (abstinent on a long -term and persistent basis) and 
agree to remain abstinent .
OR
Must agree to use contraception/barrier as detailed below:
Agree to use a male condom and should also be advised of the benefit for a 
female partner to use a highl y effective method of contraception as a condom may 
break or leak when having sexual intercourse with a woman of childbearing 
potential who is not currently  pregnant.
In addition to male condom use, a highl y effective method of contraception may be 
considered in WOCBP partners of male participants (refer to the list of highly  
effective methods below in Section 10.4.4).
10.4.2. Female Parti cipant Reproductive Inclusion Criteria
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at 
least 
1of the following conditions applies:
Is not a WOCBP (see definitions below inSection 10.4.3).
OR
Is a WOCBP and using a contraceptive method that is highly
 effective (with a failure 
rate of <1% per year), as described below, during the interv ention period and for at 
least [ADDRESS_626206] dose of study  intervention, which corresponds to the time 
needed to eliminate an y reproductive safet y risk of the study intervention(s). If a 
highl y effective method that is user dependent is chosen, a second effective method of 
contraception, as described below, must also be used. The investigator should 
evaluate the effectiveness of the contraceptive method in relationship to the first dose 
of study  intervention.

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 73The investigator is responsible for rev iew of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy . 
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the 
first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenopausal female with 1 of the following:
Documented h ysterectomy ;
Documented bilateral salpi[INVESTIGATOR_1656] ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to an alternate medical cause other than 
the above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretion 
should be applied to determining study  entry .
Note: Documentation for any  of the above categories can come from the site 
personnel’s rev iew of the participant’s medical records, medical examination, or 
medical history  interview. The method of documentation should be recorded in the 
participant’s medical record for the stud y.
2.Postmenopausal female .
A postmenopausal state is defined as no me nses for 12 months without an 
alternative medical cause. In addition :
A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years old and not using hormonal 
contraception or HRT. 
A female on HRT and whose menopausal status is in doubt will be required to 
use one of the nonestrogen hormonal highly effective contraception methods 
if they  wish to continue their HRT during the study .Otherwise, they  must 
discontinue HRT to allow confirmation of postmenopa usal status before study  
enrollment.

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 7410.4.4. Contracepti onMethods
Contraceptive use b y men or women should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
1.Implantable progest ogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device .
3.Intrauterine hormone -releasing s ystem.
4.Bilateral tubal occlusion (eg, bilateral tubal ligation).
5.Vasectomized partner .
A vasectomized partner is a highl y effective contraceptive method provided that 
the partner is the sole sexual partner of the woman of childbearing potential and 
the absence of sperm has been confirmed. If not, an additional highl y effective 
method of contraception should be used. The s perm atogenesis cy cle is 
approximately  90days.
6.Combined (estrogen- and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation .
Oral;
Intravaginal;
Transdermal .
7.Progestogen -only hormone contraception associated with inhibition of ovulation.
Oral;
Injectable .
8.Sexual abstinence .
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention. The reliability  of sexual abstinence needs to be 
evaluated in relation to the duration of the stud y and the preferred and usual 
lifesty le of the participant.

PF-[ADDRESS_626207] also be used when 
option 6 or 7 are chosen above:
Male or female condom with or without spermicide;
Cervical cap, diaphragm, or sponge with spermicide;
A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods) .
Because ritonavir may  reduce the ef fect of estradiol -containing contraceptives when agents
are coadministered, a barrier method or other nonhormonal method of contraception must
also be used if the participant is using estradiol -containing contraceptives. 

PF-07321332 
Protocol C4671019Final Protocol, 18 October 2021
PFIZER CONFIDENTIAL
Page 76 
 
 
 
 
 
 
  
 
 
 
 
 CCI
PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 7710.6. Appendix 6: Liver Safety: Suggested Actions and Follow-U p Assessments
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “tolerators,” while those who show transient liver injury  but adapt 
are termed “adaptors.” In some participant s, transaminase elevations are a harbinger of a 
more serious potential outcome. These participant s fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonl y referred to as DILI.  
Participant s who experience a transaminase elevation above 3 × ULN sh ould be monitored 
more frequently  to determine if they  are “adaptor s” or are “susceptible.”
In the majority  of DILI cases, elevations in AST and/or ALT precede TBili elevations 
(>2×ULN) by  [CONTACT_90051] s or weeks. The increase in TBili ty pi[INVESTIGATOR_487222]/AL T is/are still elevated above 3 × ULN (ie, AST/AL T and TBili values will be 
elevated within the same lab oratory sample). In rare instances, by  [CONTACT_20024], AST/ALT values might have decreased. This occurrence is still re garded as a 
potential DILI. Therefore, abnormal elevations in either AST OR ALT in addition to TBili 
that meet the criteria outlined below are considered potential DILI (assessed per Hy ’s law 
criteria) cases and should alway s be considered important medica l events, even before all 
other possible causes of liver injury  have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant ’s individual baseline values and underly ing conditions. Participant s who pres ent 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participant s with AST/ALT and TBili baseline values within the normal r ange who 
subsequently  present with AST OR AL T values >3 × ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participant s with baseline AST OR ALT ORTBili values above the ULN, the
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 × ULN; or >8 × ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).
Rises in AST/AL T and TBili s eparated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor. 

PF-[ADDRESS_626208] and AL T and TBili for suspected Hy ’s law 
cases , additional laboratory  tests should include albumin, CK, direct and indirect bilirubin, 
GGT, PT/INR, total bile acids, and alkaline phosphatase. Consideration should also be given 
to drawing a separate 
tube of clotted blood and an anticoagulated tube of blood for further 
testing, as needed, for further contemporaneous analy ses at the time of the recognized initial 
abnormalities to determine etiology . A detailed history , including relevant information, su ch 
as review of ethanol, acetaminophen /paracetamol (either by  [CONTACT_20025] a coformulated 
product in prescription or over -the-counter medications), recreational drug, or supplement 
(herbal) use and consumption, family  history , sexual history , travel history, history  of contact 
[CONTACT_4490] a jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testing for acute 
hepatitis A, B, C, D, and E infection , liver imaging (eg, biliary  tract) ,and collection of serum 
sample s for acetaminophen/paracetamol drug and/or protein adduct levels may be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 7910.7. Appe ndix 7: ECG Findings of Potential Clinical Concern
ECG Findings T hat May Q ualify as AEs
Marked sinus brad ycardia (rate <40 bpm) lasting minutes .
New PR interval prolongation >280 ms ec.
New prolongation of QTcF to >480 ms ec(absolute) or b y ≥60 msec from 
baseline .
New -onset atrial flutter or fibrillation, with controlled ventricular response rate: ie, 
rate<120 bpm .
New -
onset t ype I second -degree (Wenckebach) AV block of >30 seconds’
duration.
Frequent PVCs, triplets, or short intervals (<30 seconds) of consecutive 
ventricular complexes
.
ECG Findings T hat May Q ualify as SAEs
QTcF prolongation >500 ms ec.
New ST- T changes suggestive of my ocardial ischemia .
New -onset l eft bundle branch block (QRS >120 ms ec).
New -onset right bundle b ranch block (QRS >120 msec).
Symptomatic bradycardia .
Asystole:
In awake, s ymptom -free participant s in sinus rhy thm, with documented 
periods of as ystole ≥3.0 seconds or an y escape rate <40 bpm, or with an 
escape rh ythm that is below the AV node. 
In awake, s ymptom -free participant s with atrial fibrillation and brad ycardia 
with [ADDRESS_626209] 5 seconds or longer. 
Atrial f lutter or fibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.
Sustained s upraventricular tachycardia (rate >120 bpm) (“sustained ”= short 
duration with relevant s ymptoms or lasting >1 minute) .

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 80Ventricular r hythms >30 seconds’ duration, including idioventricular rhy thm 
(heart rate <40 bpm), accelerated idioventricular rhy thm ( HR > 40bpm to
<100 bpm), and monomorphic/pol ymorphic ventricular tach ycardia (HR 
>100 bpm (such as torsades de pointes) ).
Type II second -degree (Mobitz II) AV block.
Complete (third- degree) heart block.
ECG Findings T hat Q ualify as SAEs
Change in pattern suggestive of new m yocardial infarction .
Sustained ventricular t achy arrhy thmias (>30 seconds ’duration) .
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular response requiring 
cardiov ersion .
Ventricular fibrillation/ flutter .
At the discretion of the investigator, an y arrh ythmia classified as an adverse 
experience .
The enumerated list of major events of potential clinical concern are recommended as “alerts ”or 
notifications from the core ECG lab oratory to the investigator and [COMPANY_007] study team ,and not to be 
considered as all inclusive of what to be reported as AEs/SAEs.

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 8110.8. Appendix 8: Abbreviations
The following is a list of abbreviations that may  be used in the protocol. 
Abbreviation Term
® ongoing/continuous event
%CI confidence interval (%)
3CL 3C-like
3CLpro3C-like protein
Abs absolute
ADL activities of daily living
AE adverse event
AESI adverse event of special interest
ALT alanine aminotransferase
aPTT activated partial thromboplastin time
AST aspartate aminotransferase
AUC area under the concentration -time curve
AUC inf area under the plasma concentration -time curve from time zero extrapolated to 
infinity
AUC last area under the plasma concentration -time curve from time zero to the time of 
the last measurable concentration
AUC tau area under the plasma concentration -time profile from time zero to time tau (τ) 
the dosing interv al, where tau=12 hours for BID dosing
AV atrioventricular
BBS Biospecimen Banking System
b-hCG beta-human chorionic gonadotropin
BID twice a day
BMI body mass index
BP blood pressure
bpm beats per minute
BUN blood urea nitrogen
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD -EPI [INVESTIGATOR_82351] -Epi[INVESTIGATOR_487223]/F apparent clearance of drug from eg, plasma
Clast last observed (quantifiable) plasma concentration
Cmax maximum observed plasma concentration
CO 2 carbon dioxide (bicarbonate)
COVID -[ADDRESS_626210]-in-human
fm fraction metabolized
FSH follicle stimulating hormone
GCP Good Clinical Practice
GGT gamma -glutamyl transferase
GLP Good Laboratory Practice
HBcAb hepatitis B core antibody
HBsAb hepatitis B surface antibody
HBsAg hepatitis B surface antigen
HCoV human coronavirus 
HCoV-229E human coronavirus 229E
HCoV-HKU1 human coronavirus HKU1
HCoV-NL63 human coronavirus NL63
HCoV-OC43 human coronavirus OC43
HCV hepatitis C virus
HCVAb hepatitis C antibody
HIV human immunodeficiency virus
HR heart rate
HRT hormone replacement therapy
IB Investigator’s Brochure
ICD informed consent document
ICH International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use
ID identification
IND Investigational New Drug 
INR international normalized ratio
IPAL Investigational Product Accountability Log
IQMP Independent Qualified Medical Practitioners
IRB Institutional Review Board
IV Intravenous (ly)
kel terminal phase rate constant calculated by a linear regression of the log -linear 
concentration -time curve.

PF-[ADDRESS_626211] Respi[INVESTIGATOR_487224] d
n number of participants
N/A not applicable
NHP non-human primate
NOAEL no observed adverse effect level
PCR polymerase chain reaction
PD pharmacodynamic(s)
PE physical examination
pH potential of hydrogen
PK pharmacokinetic(s)
PR pulse rate
PT prothrombin time
PT-INR prothrombin time-international normalized ratio
PVC premature ventricular contraction/complex
q12h every [ADDRESS_626212]
QTc corrected QT interval
QTcF QTc corrected using Fridericia’s formula
qual qualitative
RBC red blood cell
Rac accumulation ratio
Rac,Cmax accumulation ratio based on C max㧦
RR respi[INVESTIGATOR_487225]-PCR reverse-transcriptase polymerase chain reaction
SAD single ascending dose
SAE serious adverse event
SAP Statistical Analysis Plan
SARS-CoV-[ADDRESS_626213] upper limit of normal
US [LOCATION_002]
USPI [INVESTIGATOR_487226]/F apparent volume of distribution for extravascular dosing
WBC white blood cell
WHO World Health Organization
WOCBP woman/women of childbearing potential

PF-07321332 
Protocol C4671019
Final Protocol , 18 October 2021
PFIZER CONFIDENTIAL
Page 8511.REFERENCES
1WHO Situation Report 51. 11 March 2020 Available from: 
https://www.who.int/emergencies/diseases/novel- coronavirus- 2019/situation -reports. 
Accessed: 29 March 2020.
2Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3CLpro) 
structure: basis fo r design of anti -SARS drugs. Science 2003;300:1763-7.
3Investigator’s Brochure, PF -07321332. (June 2021)
4Ritonavir [package insert]. North Chicago, IL: [COMPANY_013] Inc; 2017. Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209512lbl.pdf. Accessed:
12Oct2021.
5US US Food and Drug Administration. Guidance for industry : Food -Effect 
Bioavailability  and Fed Bioequivalence Studies. Rockville, MD: Center for Biologics 
Evaluation and Research; December 2002. Available from : 
https://www.fda.gov/media/[ZIP_CODE]/download. Accessed on [ADDRESS_626214] 2021.                                                
